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Phase I and II drugs within the EORTC
J.G. McVie
Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis,
1066 CX Amsterdam.
New drug development has been coordinated within the
EORTC for the last 3 years. An office in Amsterdam
oversees various stages of development from synthesis
through formulation, toxicology, pharmacology to Phase I
study. Task orientated groups conduct work on a contract
basis culminating in Phase II disease orientated trials.
Whereas the system has yet to throw up new active agents
(as opposed to new analogues), the speed and efficiency of
the process has been such that Europe can compete on equal
terms with the USA. A platinum analogue such as JM40 for
instance went through from bulk synthesis to Phase I trial in
11 months. There are currently a total of 200 drugs on file
(subfiles are shared with the NCI and the CRC Phase I
group, UK); 30 drugs in development, 10 drugs in Phase I
and 8 drugs in Phase II. Standard documents have been
published regarding guidelines for formulation, toxicology,
and preclinical pharmacology in relation to judging Phase I
starting dose, and master protocols in Phase I and Phase II
trials. Recent developments have been the use of new routes
of administration to test drugs such as intraperitoneal
chemotherapy and the development of new protocols to test
biological response modifiers.
Clinical implications of the biology of lung cancer
N. Carney
Mater Hospital, Dublin 7, Eire.
Advances over the past decade in the staging and
identification of prognostic factors in lung cancer have not
been correlated with improvements in therapeutic
approaches. However, the ease of establishment of cell lines
of both small cell (SCLC) and non SCLC (NSCLC) has led
*Enquiries to the ACP Secretariat, Department of Medical
Oncology, Christie Hospital and Holt Radium Institute, Manchester,
M20 9BX, UK.
tFor abstracts see this issue pp. 173-209.
$Reprints of these abstracts are not available - Ed.
to a greater understanding of the biological properties of
these tumours. Studies of SCLC cell lines have revealed that
the majority of these tumours express elevated levels of L-
dopa decarboxylase (DDC); bombesin (BN); neuron-specific
enolase (NSE) and creatine-kinase BB (CK-BB). In SCLC
patients serum levels of both NSE and CK-BB show an
excellent correlation with disease extent and response to
therapy. Moreover, the finding of elevated NSE, BN and
CK-BB in the CSF is highly suggestive of metastatic tumour
in this site. Heterogeneity of the expression of DDC and BN
is observed in SCLC cell lines. Variant SCLC lines (lacking
DDC and BN) are associated with a more aggressive
behaviour in vitro and in vivo and patients with variant
SCLC have a shorter survival than those with classic SCLC.
The development of numerous monoclonal antibodies has
permitted their evaluation in the imaging and detection of
tumour cells not detected by other means. Clinical trials are
underway assessing their anti-proliferative activity in vivo.
While considerable data on oncongene expression are
available for cell lines, their clinical relevance still needs to
be assessed, in particular the role of myc oncogenes in
SCLC. Finally studies of NSCLC cell lines have revealed
that 20% express biochemical features of SCLCL. Future
trials in both SCLC and NSCLC will prospectively assess the
value of tumour-endocrine properties in predicting response
to therapy and survival.
New considerations in the evaluation of staging in Hodgkin's
disease
D. Crowther
Department ofMedical Oncology, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
Since the reports of the Ann Arbor Committee on staging in
Hodgkin's disease in 1971 a number of developments have
taken place. New staging procedures such as CT scanning
and magnetic resonance imaging have been introduced to
improve tumour detection and enable more accurate
estimates of bulk and extent. Other investigations such as
lung tomography, IVP, inferior cavography have become
unnecessary in the light of these observations. The increased
use of needle biopsy techniques and immunohistochemistry
to detect disease in suspicious areas have improved the
accuracy of staging. In addition, it has been recognised that
features other than stage, as defined in the Ann Arbor
Staging Classification are of prognostic importance and may
be helpful in making treatment decisions. Features such as
age, blood lymphocyte count, ESR, bulk of disease, number
of nodal and extra nodal sites of involvement have been
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shown to be of prognostic importance using multivariate
analyses. A standard approach to pretreatment evaluation,
taking into account all prognostic features, will facilitate
communication and exchange of information. The role of
subgrouping according to prognostic indices is not yet
defined, but future analysis will be improved if known
prognostic factors are recorded and subgrouping on this
basis may be helpful in defining management policies.
Developments in the chemotherapy of multiple myeloma
P. Selby
Section ofMedicine, Institute ofCancer Research, Royal
Marsden Hospital, Sutton, Surrey, UK.
Conventional chemotherapy produces improvement in some
50% of patients with multiple myeloma and prolongs
median survival to two or three years. Complete remission of
multiple myeloma is unusual and the disease is not curable.
We have explored the use of high dose melphalan with and
without the addition of methylprednisolone in the manage-
ment of myeloma and found a complete remission rate of
almost 30% and the majority of other patients obtain partial
remissions. The quality of their remission seems excellent
but unfortunately the median duration of complete remission
is only 19 months in both of these studies. In our present
study we are exploring initial chemotherapy with vincristine
and adriamycin by 4-day infusion together with high doses
of methylprednisolone. Patients who respond sufficiently to
clear most of the myeloma from their bone marrow are
then treated with high dose melphalan and autologous bone
marrow grafting. This programme is feasible and ABMT
considerably reduces the duration and severity of the toxi-
city from high dose melphalan. The ultimate therapeutic
advantage will only be assessed after prolonged follow up.
The clinical results to date and parallel laboratory studies
on the assessment of residual disease and the biology of
myeloma will be presented.
Combined modality approaches for the treatment of epithelial
cancer of the ovary (EOC)
G. Blackledge, F. Lawton, C. Redman, D. Luesley,
J. Mould, N. Stuart & K.K. Chan
West Midlands Ovarian Cancer Group (WMOCG), West
Midlands CRC Clinical Trials Unit, Queen Elizabeth
Hospital, Birmingham, UK.
Recent randomised trials of chemotherapy have failed to
show long term survival benefit for cis-platinum based
combination regimens compared with single alkylating agent
treatment. Whilst second look laparotomy can be of
prognostic importance, no study has shown any therapeutic
benefit from second operations. Radiotherapy may benefit
some patients with no macroscopic disease after first surgery,
but studies show that radiotherapy given after chemotherapy
does not confer any survival benefit, and may be detrimental
to some patients.
In view of these findings, it might be suggested that
routine therapy for advanced EOC should consist of initial
surgery followed only by single alkylating agent chemo-
therapy, accepting that no improvements in survival can be
made, and thus minimising toxicity in a palliative situation.
The WMOCG has been carrying out a series of studies to
determine whether combined modality approaches might
offer benefit to some sub-groups of patients with EOC.
These studies have centred on three questions: (a) can a
short induction course of intensive chemotherapy adequately
debulk EOC? (b) can the integration of very early second
surgery improve the prognosis for patients with bulky
disease? and (c) can the management of adequately debulked
EOC be improved?
Initial chemotherapy studies using first alternating chemo-
therapy, and then 3 courses of cis-platinum combination
therapy followed by alkylating agent, suggested that
chemical debulking could be achieved in -80% of cases
with only 3 courses of cis-platinum based treatment. After 2
or 3 courses second surgery (intervention debulking surgery
- IDS), could be carried out resulting in no macroscopic or
<1 cm disease in 80% of cases. The potential for further
effective therapy in these cases exists.
This experimental approach is now being tested
prospectively in a randomised trial, comparing two chemo-
therapy regimens, and also randomising patients with bulky
disease after primary surgery to IDS or no IDS. Fifty
patients have so far been recruited in 10 months, and 31 of
these are eligible for randomisation to further surgery or not.
In patients who have been optimally debulked at first
operation, the potential of intraperitoneal therapy is being
investigated following systemic therapy. Combinations of
active but less toxic drugs offer the potential for long term
survival in this group, without concomitant toxicity.
In patients with no macroscopic disease following primary
surgery, a randomised trial of abdominal radiotherapy versus
cis-platinum chemotherapy is being carried out. Preliminary
results suggest that active chemotherapy is as good as
radiotherapy in this setting, with less long term toxicity.
The identification ofpatient sub-groups in EOC has meant
that potential improvements in management can be applied
to these groups and any genuine improvement in survival
will not be masked by the whole population.
Abstracts of members' proffered papers
Breast cancer
Expression of oestrogen receptor mRNA in human breast
cancer biopsies
P.J. Barrett-Lee, M.T. Travers, T.A. McDonnell &
R.C. Coombes
Ludwig Institutefor Cancer Research, St George's Hospital
Medical School, Cranmer Terrace, London SW17 ORE, UK.
Oestrogen receptors (ER) can be detected in over 50% of
human breast cancers either by the dextran coated charcoal
(DCC) assay, or using specific monoclonal antibodies
(ERICA). Determination of ER status is important in
optimal treatment planning since 70% of these ER-
positive tumours respond to endocrine therapy compared
with <5% of ER-negative tumours. In order to obtain an
improved predictive test, we have examined the levels of
transcripts for ER in tumour tissue.
Levels of ERmRNA were determined in 19 primary breast
cancers using a 1.3 kilobase (kb) ERcDNA clone. Dot blot
hybridisation analysis of total RNA extracted from these
tumours and subsequent densitometry allowed quantification212 SECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS
of ERmRNA levels. These were compared with results
obtained from the ERICA and DCC assays in each case.
Six of 19 tumours had no detectable ERmRNA and 5 of
these were ER-negative (DCC<10). Thirteen of 19 tumours
demonstrated significant expression of ERmRNA and 12 of
these were ER-positive (DCC> 10). One tumour with a
DCC<10 showed high levels of ERmRNA. However the
ERICA in this case was strongly positive. Overall there was
a positive correlation between ERmRNA and DCC assay
(rsO.56, P<0.02) and a stronger correlation with ERICA
(rsO.70, P<0.001).
These results show that both ERICA and DCC assays
correlate with levels of ERmRNA and that ER-negative
tumours produce no measurable ERmRNA. We are
currently investigating the quantitative relationships between
different mRNA's and subsequent response to endocrine
therapy.
Relationship between breast adipose tissue 17B hydroxysteroid
dehydrogenase activity and response of breast cancer to
systemic therapy
J.S. O'Neill & W.R. Miller
Department ofClinical Surgery, University ofEdinburgh,
Royal Infirmary, Edinburgh EH3 9YW, UK.
Recent investigations have suggested that steroid metabolism
in breast adipose tissue may play a significant role in the
natural history of breast tumours (O'Neill & Miller, J.
Endocrinol., 108 (suppl.), 106, 1986). In this study, 17B
hydroxysteroid dehydrogenase (17BOHSD) activity has been
measured in breast adipose tissue obtained from 16 patients
with breast cancer immediately following systemic treatment
(7 received endocrine therapy, 9 chemotherapy). The aim of
the study was to relate enzyme activity (monitored by the
conversion of androstenedone to testosterone) to the response
to therapy. Complete responses to therapy were seen in 3
patients and partial responses in 9. Four patients failed to
respond. Significantly higher 17BOHSD activity was found
in non-responders (median 4.1 pmol testosteronemg-1
protein h- 1 (units)) than in responders (median 0.8 units
(P<0.02 by Wilcoxon rank test)). Particularly low levels
occurred in adipose tissue from patients who achieved a
complete clinical and pathological remission. These results
provide clear evidence of an interaction between breast
cancers and the tissues in which they develop. Whether
the level of enzyme activity in adipose tissue adjacent to
tumours is influenced by tumour presence or is an indicator
of the responsiveness of a tumour to therapy remains to be
determined.
Fibroblasts stimulate the growth of MCF7 human breast
cancer xenografts
K. Horgan, D. Jones, & R.E. Mansel
Department ofSurgery, University of Wales College of
Medicine, Heath Park, Cardiff CF4 4XN, UK.
Stromal factors have been implicated in the regulation of
mammary epithelial cell growth in the rodent but their
influence on human breast cancer is unknown (Durnberger
& Kratochwil, Cell, 19, 465, 1980). Fibroblasts were grown
in monolayer cell culture from explants of benign and
malignant breast tissue and normal skin. MCF7 human
breast cancer cells alone (2x 106 cells) or in combination
with live breast or skin fibroblasts (MCF7+BF,
MCF7+SF) were inoculated into the mammary fat pads of
female nude mice. After 5 weeks tumours were excised,




tumours retrieved 52/106a 127/135b 18/19b
tumour weight (mg) 41 +4c 174+ ld 139+16d
aVS. bp<0.O0j Chi square; CVS. dp<0.001 Mann-Whitney.
Addition of live fibroblasts to MCF7 inocula significantly
increased the number and growth of subsequent tumours.
Tumour formation was not observed after injection of
fibroblasts alone. Histological examination did not reveal
any obvious differences between the tumour groups.
These experiments demonstrate a highly stimulatory role
for fibroblasts in inducing human breast cancer tumori-
genesis in nude mice.
PCM42 xenografts: A new experimental model to study
human breast cancer differentiation
K. Horgan, D. Jones & R.E. Mansel
Department ofSurgery, University of Wales College of
Medicine, Heath Park, CardiffCF4 4XN, UK
PMC42 is a unique human breast carcinoma cell line that
differentiates both morphologically and functionally in vitro
and is stimulated by prolactin and EGF (Whitehead et al.,
J. Natl Cancer Inst., 70, 649, 1983). Previous efforts to
transplant PMC42 cells from monolayer culture into nude
mice have failed, but fibroblasts have recently been shown to
stimulate other human breast cancer xenografts.
PMC42 cells alone (2-4 x 106 cells) or in combination with
human breast fibroblasts (PMC+F) were inoculated into the
mammary fat pads of female nude mice. After 6-8 weeks the
mice were sacrificed and the mammary fat pads excised and
fixed for serial histological sectioning.
The results showed no tumour formation from 16
injections of PMC42 alone while 26 or 36 PMC+F inocula
were successful. Histological examination demonstrated
marked cellular organisation with many tubules or ductulo-
alveolar like structures. Ultrastructural features included
luminal microvilli characteristic of secretory cells, a basement
membrane and inter-cellular junctions. The xenograft
PMC42 stained strongly with monoclonal antibodies against
human milk fat globule membrane while in vitro cultures
were negative.
We conclude that the addition of fibroblasts allows growth
of PMC42 xenografts in nude mice providing a new and
valuable experimental model for the investigation of breast
cancer differentiation and hormonal response.
The effect of tamoxifen upon progesterone receptor (PR)
concentrations and of cyclical endocrine therapy with
tamoxifen (T) and medroxyprogesterone acetate (MPA) in
patients with advanced cancer of the breast
H. Anderson, A. Howell, D.B. Smith, R.A. Cowan,
D.M. Barnes & R.N.L. Harland
CRC Department Medical Oncology & Department ofClinical
Research, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
In the human mammary tumour cell lines, MCF-7, T
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agonist effect. The aim of this study was to determine
whether an effect of T on PR synthesis could be shown in
human mammary tumours in vivo and to test the
effectiveness of cyclical endocrine therapy which might
capitalise on the T effect. PR was measured in biopsies taken
(a) before and after a median of 13 days T in 52 patients
with advanced disease and (b) after a median of 7 days T in
58 patients with primary disease: controls (C) were 51 with
primary disease who had 2 biopsies 7 days apart, but no T.
Mean PR (+ s.e.) in those with higher PR in the second
biopsy was (a) 237 +78, (b) 318 + 135 and (c)
71 +21 fmol mg - I cytosol protein (a vs. c P =0.03, b vs. c
P=0.03). Nineteen of 21 (90%) advanced disease patients
with a higher PR in the second biopsy subsequently
responded to continued tamoxifen. These data suggest that T
has agonist activity in vivo in responsive tumours and thus
the effect of cyclical T 7 days, MPA 14 days, nil 7 days etc.
(n=41) was compared with T followed by MPA at relapse
(n =39) in patients with previously untreated advanced
breast cancer (study 1). Cyclical T/MPA (n=21) was
compared with MPA (n=20) in previously treated patients
(study 2). Measurements of serum T and MPA confirmed
cyclical drug levels. In both studies the response rate and
median durations of response to T/MPA were not
significantly different to T (study 1) or MPA (study 2) alone.
In study I the median survival for T/MPA was 20 months
and for T followed by MPA was 35 months (P=NS). In
study 2 the median survival figures were 13.5 and 15 months
for cyclical and sequential treatment respectively. We
conclude that T is a partial agonist with respect to PR in
vivo and that, although tumours respond to T/MPA the
cyclical regimen is not superior to sequential treatment with
T followed by MPA at relapse.
High dose versus low dose oral medroxyprogesterone acetate
(MPA) in advanced breast cancer: A randomised trial
C.J. Gallagher, J.A. McKinna, F. Cairnduff & I.E. Smith
Breast Unit, Royal Marsden Hospital, London UK.
The majority of studies claiming benefit for high dose MPA
in advanced breast cancer are non-randomised. Dose
response for oral MPA was therefore investigated in 124
patients (pts) with advanced breast cancer randomised to
low dose (LD) 300mgday- 1 (66 pts) or high dose (HD)
1000mgday-1 (58 pts) MPA. The groups were evenly
matched for age, menopausal status, disease-free interval,
sites of disease, and previous treatment. Thirty-three pts had
received no previous endocrine therapy. Overall response
(UICC criteria) was 24% for both LD (16/66) and HD
(14/58) pts, with stable disease in a further 12 (18%) LD and
17 (29%) HD pts. Median response duration was II months
(mo) (range 2-19 mo) for LD vs. 10 mo (range 3.5-25 mo)
for HD; median survival (all pts) was 13 mo (LD) vs. 11 mo
(HD). Response by site was similar for LD and HD; relief of
bone pain occurred in 43% LD and 52% HD pts, although
objective resclerosis occurred in only 13% for both LD and
HD. For previously untreated pts, 6/19 (32%) responded to
LD and 4/14 (29%) to HD MPA. For previously treated pts,
10/47 (210%) responded to LD and 11/44 (25%) to HD
MPA. Two of 4 premenopausal pts responded to LD and
3/6 to HD (total 50% response). Both treatments were in
general well tolerated, but toxicity was greater for HD than
LD including in particular fluid retention 26% vs. 6%) and
weight gain (10% vs. 2%); and for HD treatment had to be
altered for 18% of pts (dose reduction 9%; treatment
stopped 9%) compared with treatment stopped for only 2%
of LD pts (P<0.01). LD is as effective as HD oral MPA for
advanced breast cancer, and is cheaper and less toxic.
A randomised trial of short course (9 weeks) mitoxantrone
versus continuous therapy in advanced breast cancer
A.L. Harris, B.M.J. Cantwell, S. Ghani, P. Dawes,
R.G.B. Evans, H. Lucraft, R. Wilson & J. Farndon
University Departments of Clinical Oncology, Surgery and
Radiotherapy, University of Newcastle-upon-Tyne, Newcastle-
upon-7yne, UK.
Mitoxantrone (M) 14 mgm-2 every 3 weeks was used as
first-line chemotherapy for 80 patients with advanced breast
cancer. After 4 courses (9 weeks), responders were random-
ised to continue (C) until relapse or stop (S). Patients on
the short course (S) were re-treated with M on relapse. On
relapse, C and the non-responders were treated with adria-
mycin (A) 40mgm -2 Seventy-one patients had previous
hormone therapy (median 2 types, range 1-4) and 23%
had responded. Sixty-four patients had prior radiotherapy.
Ages ranged from 28-78 years, median 57. Years from LMP
ranged from 0-40 years (median 6). Tumour-free interval
ranged from 0-181 months (median 11 months). Thirty-three
patients were performance status 2, 45 PS 1, 2 PS 0.
The response to M was 26% partial response, 8% stable
disease for >3 months. Twelve patients were randomised to
(C) and 13 to (S). There was no difference in age, years from
LMP, tumour-free interval, weight, time from first
recurrence to start of M or performance status in the 2 arms.
The median response duration was 7 vs. 8 months (S vs. C),
the median survival from start of treatment was 10 vs. 9
months (S vs. C) and survival from first recurrence 31 vs. 29
months (S vs. C). Toxicity was mild. This study shows short
course therapy is as effective as continuous therapy and
therefore chemotherapy should be stopped once response has
occurred. Drug resistance must emerge within the first 9
weeks or be present before treatment starts.
The prognostic significance of dual parameter flow cytometric
analysis of primary and metastatic breast cancer
J. Lawry' & K. Rogers2
'Department of Virology and 2Department ofSurgery, The
University ofSheffield Medical School, Beech Hill Road,
Sheffield SJO 2RX, UK.
The use of dual parameter correlated (DPC) flow cytometry
enables the simultaneous analysis of DNA cell cycle and
monoclonal antibody (MoAB) binding on the same sample,
providing valuable information on tumour heterogeneity.
Using tissue and cell specific markers to cytokeratin, human
milk fat globulin and infiltrating T-cells, in conjunction with
the DNA fluorochrome propidium iodide, samples can be
subdivided into cells which are MoAB positive or negative,
diploid or aneuploid, and proliferating or non-proliferating
simultaneously.
Results of these multiparameter analyses for 28 primary
breast tumours, 15 lymph node metastases, and 4 samples of
normal breast tissue taken at mastectomy, correlated to
clinical stage and histological grade, infer a role for DPC
flow cytometric analysis in assessing disease status, not
achievable by single parameter DNA analysis. Furthermore,
due to the ability to sub-classify a heterogeneous tumour
sample into several populations of cells, the identification of
possible sites of metastatic spread may be made more
accurate, and clinically relevant.214 SECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS
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Preclinical screening of new anticancer agents using panels of
human continuous cell lines
W.E.A. Jenkins', R.H. Shoemaker2 & J.R.W. Masters'
Department ofHistopathology, Institute of Urology, St
Paul's Hospital, 24 Endell Street, London WC2H 9AE,
2Division of Cancer Treatment, National Cancer Institute,
Bethesda, Maryland 20892, USA.
The use of continuous cell lines as a model for the in vitro
pre-clinical screening of new anticancer agents was
investigated. We compared the in vitro sensitivities to 12
novel agents (obtained from the NCI) of 5 lines derived from
transitional cell carcinomas of the human bladder (RT4,
RT112, T24, HT1376, HT1197), 4 from non-seminomatous
testicular germ cell tumours (SuSa, 833K, 1618K, GH) and 2
from normal human urothelium (HU609, HS0767).
Cytotoxicity was assessed by inhibition of colony forming
ability during continuous exposure to a range of drug
concentrations. Parallel assessments are being made of these
agents in vitro using the human tumour stem cell assay
(HTCSA) and in vivo using the transplantable murine P388
tumour and 2 human tumour xenografts, and where
appropriate in clinical trial. In this study, 3 agents displayed
no cytotoxicity up to a maximum concentration of
40 ug ml-1. Seven drugs were active in the concentration
range l-8pgmlr', one between 0.3 and 2.0 gml- and the
most cytotoxic agent inhibited colony development in the
range 30-100 ngml- '. In keeping with clinical experience,
the testicular tumour cells were generally more sensitive than
the bladder cancer cell lines, with the exception of one drug
to which the pattern was reversed. The 'normal' cell lines
were, on average, more sensitive to the agents than the
bladder cancer cell lines, and thus this comparison failed to
demonstrate differential cytotoxicity to tumour cells. In
terms of relative cytotoxicities, the data obtained using the
cell lines and the HTCSA were similar, and for this purpose
cell lines are more reproducible and cost-effective.
A novel strategy for dose escalation in phase I clinical trials of
chemotherapeutic agents
D.B. Smith ' & C. Ewen2
Department of Medical Oncology and 2Paterson Institute for
Cancer Research, Chlristie Hospital and Holt Radium
Institute, Manchester M20 9BX, UK.
Dose escalation in Phase I clinical trials must strike a
balance between the risk of excessive toxicity due to rapid
increases and treating many patients at ineffective doses
through over-conservative increments. The following data
were obtained from a review of 61 Phase I trials published
since 1970:
Escalation: Fibonacci 41 (67%) steps to 1st toxicity
median, range 3 (0-7).
50-100% 12 (20%) steps to MTD imedian, riange 7 (0-15).
Starting dose: mouse 23; dog 23; monkey 2; unspecified 13.
Forty-three per cent of patients overall received less than the
dose recommended for Phase II, and toxic deaths occurred
in 12 trials (20%). In only 5 trials was the MTD <5 x the
starting dose (5n) and in each case toxicity was seen at the
starting dose. Thus in all 61 trials it would have been safe to
escalate to 5n if the starting dose was found to be non-toxic.
Subsequent escalations may be guided by pharmacokinetic
data. Collins et al. (Cancer Treat. Rep., 70, 73, 1986) have
shown a close correlation between the AUC at the mouse
LD1O and the AUC in the MTD in man. Comparison of the
AUC at Sn with mouse data will allow rational selection of
the next escalation step. This should not normally exceed
100% since the AUC may rise more rapidly than expected in
drugs exhibiting non-linear kinetics. A Phase I trial of the
new spindle poison ICI 134,154 has been carried out using
this scheme. The AUC at the mouse LDI 0 was
313 ,ug 1- I h - 1. The starting dose was 40mgm -2 (1/10 LDIO
mouse). The AUC at 200mgm-2 was ll ugl-lh- and at
400mgm-2 was 39 g -lh-1. Two patients have received
800mgm 2. In one the AUC was 116pgl h 1 and in the
other 228 jugl-lh-1. The latter patient developed alopecia
and a WBC nadir of 1.4 x 1091- 1. This, therefore, appears to
be close to the MTD. Using the methods outlined the
numbers of patients treated at ineffective doses and the
duration of Phase I trials may be reduced by up to 50%.
A Phase I study of meta-azidopyrimethamine ethane
sulphonate (MZPES) - a new dihydrofolate reductase inhibitor
N.S.A. Stuart', M. Crawford2, G.R.P. Blackledgel,
E.S. Newlands2, J. Slack3, R. Hoffman2, J. Kavanagh',
M. MacKenzie' & D.S. Northcott2
'Queen Elizabeth Hospital, Birmingham, 2Charing Cross
Hospital, London and 3University ofAston, Birmingham, UK.
MZPES is a new dihydrofolate reductase (DHFR) inhibitor
of the diaminopyrimethamine group first synthesised in 1978.
It has the potential advantage of methotrexate, the standard
DHFR inhibitor, of being lipophilic thus being able to cross
the blood-brain barrier and also possibly overcome
transport-mediated drug resistance by passive diffusion. It
also has a relatively short half-life compared to other similar
compounds raising the possibility of reduced toxicity to
normal tissues. Animal studies have shown activity against
L1210 leukaemia (+ +), B16 melanoma (+ +), M5076
reticulum cell sarcoma (+ +), P388 leukaemia (+) and
TLXS lymphoma (+).
MZP is undergoing Phase I assessment in advanced
malignancies unresponsive to standard treatment being
administered in 5% dextrose as a I h i.v. infusion. Starting
dose was 10% of the LD1O in mice, i.e. 5.4mgm-2 with
dose increments to 11, 18, 27, 38, 50, 67, 83, 105, 125, 150,
180, 210, 250, 300, 360 and 400mgm 2 Sixty-two patients
have received 128 courses. Toxicity has comprised (a) nausea
and vomiting (WHO grade 3/4) at doses of 180mgm-2 or
more; (b) light-headedness, dizziness, incoordination and
malaise at doses of 300mgm -2 or more; (c) Leucopenia
(WBC <3.5 x 1091 -1) in 4/35 courses and thrombocytopenia
(platelets < 150 x 1091- 1) in 4/35 courses above 210mgm 2
One patient who had brain metastases developed generalised
convulsions immediately following 210mgm-2. EEG
recordings during and after infusion in subsequent patients
receiving 210 and 250 mgm-2 showed no abnormalities. One
patient suddenly became unconscious 20h after 400mgm 2
He had clinical signs of an intra-cranial bleed, remained
comatose and died. Post-mortem was refused. Pharmaco-
kinetics studies at all doses except 5.4mgm-2 indicate the
drug obeys 2-compartment kinetics with an elimination half-
life of 37 h. No responses have been seen.
MZPES is a novel DHFR inhibitor with interesting
chemical properties and good anti-tumour activity in murine
tumour models. This study suggests that maximum tolerated
dose when administered by 1 h i.v. infusion will be in the
range 400-500mgm -2 with dose limiting toxicity being
neurological symptoms and nausea and vomiting. Further
study is required to determine whether this drug has anti-
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Phase I clinical and pharmacokinetic study of flavone acetic
acid
C. Bradley', S.B. Kaye', D.J. Kerr', A. Setanoians',
J. Cassidy', L. Adams', E.M. Rankin', T. Young2,
G. Forrest2 & M. Soukop2
Departments ofMedical Oncology, 'Glasgow University and
2Glasgow Royal Infirmary, UK.
Flavone acetic acid, a synthetic flavonoid aglycone, is active
in a range of murine tumours refractory to conventional
cytotoxic agents. A therapeutic plasma window of 100-
500 pgml was described in mice and it was noted that
cytotoxic efficacy was related to the duration of drug
exposure above the therapeutic threshold. Forty-three
patients (median age, 55 years, median performance status,
1) with predominantly metastatic colorectal carcinoma were
entered in the Phase I trial. Three patients were entered at
each dose level and escalation was by a modified Fibonacci
regime. Drug was administered weekly (x 3) with
bicarbonate (1.26%) by a I h infusion initially and
subsequently 3 and 6 h infusions. Dose limiting toxicity for
I h infusion (at 6.4gm-2) consisted of intolerable flushing
and a sensation of warmth. The peak drug level obtained
(with I h infusion) was 1,225 pgml - 1. The drug demon-
strated non-linear pharmacokinetics over the dose range
of 500 mg to 6.4 gm-2. Further dose increments using a
6 h infusion were performed and the current entry dose is
10gm-2. Dose limiting toxicity using a 6 h infusion has not
yet been reached, although one episode of hypotension has
been noted. The peak drug level with a 6 h infusion (at
8.6gm 2) is 650,pgml ', but calculations of AUC
(>100pg ml '-) confirm that greater drug exposure is
obtained using longer infusion. No responses have yet been
seen, but since murine therapeutic levels are clinically
achievable, Phase II trials are planned through the Cancer
Research Campaign Phase II Committee using the 6 h
infusion schedule.
Site dependant sensitivity of a transplantable mouse colon
tumour to flavone acetic acid (LM975)
J.A. Double, M.C. Bibby & R.M. Phillips
Clinical Oncology Unit, University ofBradJfrd, BradfJrd,
West Yorkshire BD7 ]DP, UK.
Previous studies with flavone acetic acid, LM975, (Bibby
et al., Br. J. Cancer, in press, 1987) have demonstrated
spectacular responses of established s.c. solid transplantable
colon tumours in mice (MAC tumours). The plasma profiles
of LM975 associated with this activity have now been
attained in man (Kerr et al., 1986 Proceedings of the Fifth
NCI/EORTC Symposium on New Drugs in Cancer Therapy,
Amsterdam) but no responses have yet been seen. The
present study attempts to explain this by examining the
chemosensitivity to LM975 of transplantable adeno-
carcinomas of the mouse colon grown in different sites.
MAC 15A is an ascitic variant of MAC 15 and i.v.
administration of the ascites cells produces systemic disease.
Responses to chemotherapy are measured by a survival assay
and are essentially the same for standard agents as those
seen with the solid and ascitic variants. The best responses to
date are seen with the nitrosoureas. Subcutaneous
inoculation of ascites tumour cells produces a poorly
differentiated tumour which is sensitive to intraperitoneal
treatment with LM975. Neither the ascites tumour nor the
systemic disease responds to LM975. The lack of response of
the ascites tumour may be explained by rapid peritoneal
clearance whereas it is difficult to envisage a pharma-
cokinetic explanation for the insensitivity of the systemic
model. Preliminary in vitro studies with MAC15A suggest
that plateau phase cells are 4 times more sensitive than log
phase cells to LM975 indicating that cell kinetics may be an
important factor in determining response. These results have
demonstrated the importance of tumour site in determining
chemosensitivity to LM975 and this fact should be taken
into account in the assessment of its clinical activity.
Continuous infusion chemotherapy with ifosfamide (IFX) -
pharmacokinetics, toxicity, efficacy
L.D. Lewis, J. Warin2 & C.G. Rowland2
'Department of Clinical Pharmacology, United Medical and
Dental Schools, Guy's Hospital, London SEI 9RT and
2Department of Radiotherapy, Royal Devon and Exeter
Hospital, Exeter, UK.
IFX is an alkylating agent which has proved effective in the
treatment of a number of neoplastic disorders. Certain
chemotherapeutic agents e.g. vinblastine and bleomycin
(Samuels et al., Cancer Chem. Rep., 59, 563, 1978), have
proven more effective without increased toxicity when given
by long term i.v. infusions.
We studied 6 patients (3 male), median age 64.5 (range
55-72) yrs, median Karnofsky score 90 (range 90-100), 4
had inoperable bronchial ca., 1 adeno ca. ovary, 1
transitional ca. bladder. They received home based treatment
(3 cycles) of IFX 1 g and mesna 800mg infused i.v. (by a
battery driven syringe pump attached to a CVP line) every
24h for 10 days at monthly intervals.
We performed pharmacokinetic studies on 8 courses (2
patients were studied on 2 occasions) prior to therapy and at
timed intervals at the end of the infusion blood samples were
taken. Plasma IFX concentrations and alkylating activity
were measured using published GLC and spectrophotometric
methods respectively.
Pharmacokinetic results (n=8) median (range): plasma
IFX elimination half-life=6.0 (3.9-8.7) h; AUC 1,907.7
(1,056.2-2,2929.1) pgml -'; Css IFX 7.95 (4.4-12.2) pgml -;
IFX clearance=87.5 (56.9-157.8) mlmin-1; Vd=619.9
(471.1-996.6) ml kg- 1. No plasma alkylating activity was
detected. In several of the patients analysing intermittently
obtained urine samples alkylating activity was qualitatively
detected.
Three of 6 patients had slight nausea, 4/6 mild alopecia,
1/6 had proteinuria, no haematological toxicity or
haematuria was noted. Three of 6 had a partial response.
This treatment regime produces no detectable plasma IFX
metabolites, very good tolerance and a good tumour
response.
Pharmacokinetics of intravenous and oral mesna
C.A. James, T.G.K. Mant, H.J. Rogers & P.G. Harper
Department of Clinical Pharmacology, United Medical and
Dental Schools, Guy'.s Hospital, London SE] 9RT, UK.
Mesna (sodium 2-mercaptoethane sulphonate) prevents the
urotoxic side effects of the oxazaphosphorines. We have
investigated its pharmacokinetics in 6 healthy volunteers (3
male) who received 800mg of mesna by i.v. and oral routes.
Mesna and dimesna (the sole metabolite) were measured
in plasma and urine by reverse-phase ion-pair HPLC
followed by electrochemical detection (James & Rogers, J.
Chromatogr., 382, 394, 1986).
Following i.v. injection plasma mesna concentrations were
fitted by a one compartment model with mean +s.d. t112
22.0+ 3.1 min. The terminal t1/2 for dimesna was
1.17 +0.32 h. Following oral mesna the lag time before216 SECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS
appearance of mesna varied from 0.33 h to 2.5 h and for
dimesna from 0.25 to 0.5 h with late peaks of mesna and
dimesna concentrations (little free mesna was detected in the
plasma of 2 subjects).
After i.v. administration most of the urinary mesna
excretion occurred in the first 4h. After oral dosing mesna
excretion was more prolonged over 8 h, although generally
more was excreted in the first 4h. A mean of 31.8+1%
of the dose was excreted as mesna after the i.v. dose
and 17.6+9.2% after p.o. Total urinary excretion
(mesna+dimesna) over 24h was 65.1 + 11.4% after i.v. and
49.3 + 13.7% following p.o. dosing.
The urinary bioavailability of free mesna was 53.0+19.5%.
The formal oral systemic bioavailability based on the renal
excretions of mesna and dimesna was 76.1 + 16.1%.
These results suggest that oral doses of mesna should be
double those used for i.v. and that either the first oral dose
should be given 2 h before the oxazaphosphorine, or an
initial i.v. dose should be given with the oral dose.
Mitozolamide: Phase II studies in melanoma, lung and ovarian
cancer
M. Harding', S.B. Kaye', A. Dorward3, R. Mackie2,
J. Smythe4 & G. Blackledge5
Departments of IMedical Oncology and 2Dermatology,
University ofGlasgow, 3Royal Alexandra Infirmary, Paisley,
4Department ofMedical Oncology, University oJ Edinburgh
and 'Department of Medicine, University of Birmingham, UK.
Mitozolamide, a novel cytotoxic agent structurally similar to
the chlorethyl-nitrosoureas, has shown significant preclinical
activity in murine tumours and human tumour xenografts.
The initial dose in these Phase II trials was 115mg m -2
orally, with retreatment planned for 6 weekly intervals, in
71 patients. Severe thrombocytopenia (median nadir
29x 1091-') occurred in the first 11 lung cancer patients.
The dose was reduced to 90mgm -2 or 70mgm -2 for
heavily pretreated patients. Gastrointestinal toxicity was mild
(grade 0-2). Unpredictable myelosuppression occurred
despite dose reduction: median nadir values 2.6-4.8 x 1091 1
WBC; 60-131 x 1091 platelets, but Grade IV thrombo-
cytopenia was still seen. This contributed to 5 patient deaths
within 7 weeks of treatment. Only 31 patients received 2 or
more cycles at 6-8 week intervals because of delayed myelo-
suppression (nadir WBC 5-6 weeks).
Inevall
Tumour Number too early PR SD PD
Lung (non small cell) 15 3 - 4 8
Lung (small cell) 20 2 5 2 11
Melanoma 16 - 2 2 12
Ovary 20 6 - 3 11
These preliminary data indicate activity in small cell lung
cancer (3 PR in 11 pretreated, 2 PR in 9 previously
untreated patients) but response duration was short (6-26
weeks). Activity in melanoma requires confirmation, and
resistance of ovarian cancer may reflect extensive prior
therapy. Clinical application of mitozolamide, particularly in
combinations, would be difficult because of unpredictable
and frequently cumulative myelosuppression. The ovarian
cancer study was performed by the Cancer Research
Campaign Phase II Committee.
Phase I study of recombinant human tumour necrosis factor
P. Selby, K. Fearon, H. Calvert, S. Hobbs, C. Viner, J. Hall
& T.J. McElwain
Sections of Medicine, Nursing and Biomedical Pharmacology,
Institute of Cancer Research, Sutton and Department of
Medical Oncology, GlasgowN Royal Infirmary, UK.
Tumour Necrosis Factor is a protein produced by mammals
after challenge with bacterial endotoxins. It is cytotoxic in
vitro for human tumour cell lines and produced necrosis and
regression of experimental murine tumours. It is also a
potent inhibitor of lipoprotein lipase synthesis in vitro
(cachectin). Large quantities of pure protein are available as
a result of expression of the gene in E. coli.
A Phase I study of human recombinant TNF is reported
here. The drug was given by a 1 h infusion repeated every 2
weekly period for 3 doses with one dose escalation for the
third treatment. Three patients at each dose level. Treatment
began at a dose of 1/1,000th of the murine LDIO equivalent
(9x l03Um-2) and was escalated to 1.2x l06Um-2.
Eighteen patients with malignancies unresponsive to
conventional therapy were treated.
All patients experienced fever with rigors but this reaction
was significantly reduced by pretreatments with steroids
and indomethacin. At doses of 6-12 x 0o U m-2 patients
developed abnormal liver function tests, transient hypo-
tension, transient leucopenia and changes in serum
creatinine. The maximum safe dose appears to be
_1 X 106 Um-2. Lipid tolerance tests revealed no inhibition
of triglyceride clearance. Pharmacokinetic studies showed
rapid clearance (t,12 '20min). Two patients, both with
lymphoma, showed evidence of response to therapy.
Ovarian and gonadal tumours
Randomised trial comparing abdomino-pelvic radiotherapy
with cis-platinum in patients with ovarian cancer with no
macroscopic disease after primary surgery
C.W.E. Redman, F.D. Lawton, D. Luesley, C. Hilton,
J. Mould, T. Latief, K.K. Chan & G. Blackledge
CRC Clinical Trials Unit, Queen Elizabeth Hospital,
Edgbaston, Birmingham, UK.
The objective of this study was to compare radiotherapy, as
described by Dembo et al. (J. Rad. Oncol. Biol. Phys., 5,
1933, 1978) with single agent cis-platinum in the
management of patients with no macroscopic disease after
primary surgery. Between October 1981 and October 1986 37
patients were randomised to receive either pelvic plus
abdomino-pelvic irradiation, using the moving strip
technique (2250 cGy midplane; total dose to pelvis
4,500 cGy) or 5 courses of single agent cis-platinum
(lOOmgm-2 i.v. every 21 days). Data on the first 28 patients
is available for analysis. Fourteen patients were randomised
into each treatment group. The two groups were comparable
for age, tumour histology and differentiation, and FIGO
staging (Ic to III). Three of 14 patients, all in the
chemotherapy arm, did not receive full protocol therapy (2
patients received only 4 courses because of toxicity; 1 patient
received 5 courses but at reduced dosage).
The study group has had a median follow-up of 37
months and 71% are alive at 48 months. There have been 4
disease-related deaths and I unrelated death in the radio-
therapy group; there was progressive disease noted at the
end treatment in 3/4 of the disease related deaths. There
have been 3 deaths in the chemotherapy group. There is no
significant difference in survival between the two groups (logSECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS 217
rank chi square (I df)=0.900; P=0.34). Two patients, one
from each group, have evidence of recurrent disease. Three
patients in the radiotherapy arm have experienced radiation
induced enteritis requiring surgical management. These
preliminary results attest to the favourable prognosis of
patients with no macroscopic disease following primary
surgery. At this stage, there is no significant survival
difference between the two groups, although there is long
term morbidity from significant radiation induced enteritis.
Further follow-up is required to determine whether cis-
platinum will continue to give results comparable with those
achieved by radiotherapy in the study of Dembo et al.
suppression was acceptable with mean nadir WCC of 4.3
(range 1.4-9.0) and mean nadir platelet count of 273 (range
39-536) observed on day 21. There were no therapy related
infective episodes. Twenty pts are evaluable for response
including 7 pts with residual post-operative bulky tumour.
The response rate (CR=13+PR=2) was 75%. Six of the 7
patients who failed to achieve CR with treatment had
residual bulky tumour following initial surgery. Although
preliminary, these results suggest (1) carboplatin and cyclo-
phosphamide in the above dose is an active out-patient
regimen that is well tolerated in pts with newly diagnosed
ovarian cancer, (2) toxicities, including haematological renal
and auditory are minimal.
GR38032F, a selective 5-HT3 receptor antagonist, is
anti-emetic in patients receiving cytotoxic drugs
D. Cunningham', J. Hawthorn2, A. Pople3, J.-C. Gazet4,
H.T. Ford4, T. Challoner5 & R.C. Coombes1'3
'Medical Oncology Unit, 2Department ofPhysiology, 3Ludwig
Institutefor Cancer Research (London - St George's Group),
St George's Hospital Medical School, London SW17 ORE,
4St George's Hospital, London SWI7 OQT and 5Glaxo Group
Research Ltd, Ware, Herts, UK.
GR38032F (Glaxo Group Research, Ware) is a novel highly
selective 5HT3 antagonist which has been shown to be
capable of abolishing cis-platin induced emesis in the ferret.
This is the first report of the use of this class of compound
to treat emesis in patients receiving chemotherapy.
We have treated 15 patients receiving a variety of
cytotoxic drug combinations (excluding cis-platin) which had
produced nausea and vomiting refractory to first-line anti-
emetics. GR38032F, 4mg i.v. and 4mg p.o., was given
immediately prior to chemotherapy, the oral dose was then
repeated 5 and 10h later. Nausea, vomiting and side effects
were recorded for the following 24h. The 15 patients
received a total of 31 courses of chemotherapy. During this
time only 1 patient experienced vomiting. The only
noticeable side effects were dryness of the mouth in one
patient and mild sedation in one other, which were not
clearly drug related.
Results from this open study indicate that GR38032F
successfully controls refractory vomiting caused by cytotoxic
drugs with negligible side effects.
Carboplatin and cyclophosphamide chemotherapy in advanced
ovarian cancer
M. Teeling & D.N. Carney
Department ofOncology, Mater Hospital, Dublin 7, Eire
A Phase II study of carboplatin (300mgm -2 i.v.) and
cyclophosphamide (600mgm-2 i.v.) was carried out in 26
patients (pts) with newly diagnosed advanced stage ovarian
cancer. Courses were administered at 4-weekly intervals for a
total of 6 cycles. Therapy was administered as an out-patient
without prehydration or forced diuresis. Antiemetic therapy
consisted of oral high dose dexamethasone (24mgd-1) and
metoclopramide (60mgd-) commencing 12 h prior to
cytotoxic therapy. Patients were staged with CT scans
before, during and after 6 cycles of chemotherapy (CT). To
date 26 pts with FIGO stage II (2 pts with residual disease),
III & IV have received 105 cycles of chemotherapy.
Treatment was well tolerated by most patients with minimal
nausea and vomiting (WHO grade 1-2) observed during
35% of the cycles. Two patients developed moderate
alopecia. No clinical or biochemical evidence of nephro-
toxicity was seen. Tinnitus, deafness or peripheral
neuropathy have not been observed to date. Myelo-
Phase II studies of mitozantrone and platinum in advanced
epithelial ovarian cancer (EOC); an active regimen with
minimal toxicity by intravenous or intraperitoneal route
F.F. Lawton', C. Redman2, D. Luesley1, J.J. Mould3,
D. Spooner3, A.D. Chetiyawardana3 & G. Blackledge2
Departments of 'Obstetrics and Gynaecology, 2Medicine and
3Radiotherapy, Birmingham, UK.
Mitozantrone (M) can achieve 25% responses in patients
with EOC previously treated with platinum. As a result of
this activity and relative lack of toxicity, it has been
incorporated into a first-line regimen with cis-platinum (D).
Twenty-three patients (pts), 18 previously untreated, median
age 61 years, all with FIGO stage III or IV disease received
D 75-100mgm-2 and M 12-14mgm-2 i.v. q. 3 weeks for 6
cycles. Twenty pts had evaluable disease and 16 (80%)
showed at least a partial response (WHO criteria). Median
duration of remission has not yet been reached (median
follow-up 11 months). Subjective toxicity was minimal.
Sixteen pts had greater than WHO grade I emesis and 4 pts
had greater than grade II alopecia. Eleven pts had greater
than WHO grade I myelotoxicity and 11 pts required
transfusion. Three cycles of i.v.-MD could be given with
minimal myelosuppression but cumulative marrow
suppression produced treatment delay by 1 to 4 weeks in 12
pts (4 at cycle 3, 5 at cycle 4, 3 at cycle 5) and in 8 pts
treatment was discontinued after 5 cycles i.v.-MD because of
myelosuppression. Twelve patients with sub-optimal primary
surgery, were scheduled to undergo secondary surgical
debulking (IDS) after 2-3 courses of chemotherapy. Eight of
12 had optimal resection; 1 remained inoperable, I had had
insufficient response to MD to consider further surgery; 1
had medical contraindications, and there was I early disease
related death. These data suggest that the majority of
patients with EOC can be rendered optimally debulked by
MD and early secondary surgery. Intraperitoneal therapy is
now being used in these patients, (1) to optimise drug
concentration at the site of possible residual tumour and (2)
to minimise subsequent systemic cumulative toxicity.
Treatment plan for pts with sub-optimal primary surgery
now consists of: primary laparotomy; i.v.-MD x 3; second
surgery with insertion of indwelling i.p. catheter; i.p.-MD x 5
q. 3wks with the following dose escalation: D 100 to 200
mgm-2, M 15 to 25mgm-2 with i.v. sodium thiosulphate
infusion during the i.p. cycles. Preliminary results suggest
that these doses can be safely administered with little myelo-
suppression and minimal reduction in renal function.
Combination i.v.-MD is an active regimen in EOC with
dose limiting myelosuppression. Over 75% of pts can be
rendered to less than 2cm residual disease with a
combination of primary laparotomy, i.v.-MDx3 and IDS
and would therefore be candidates for i.p.-MD. Such
combined approaches need further evaluation in EOC.218 SECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS
Antigen expression in human ovarian adenocarcinoma cell lines
S.P. Langdon', F.G. Hay2, M.M. Hawkes', S.S. Lawrie',
R.C.F. Leonard2, J.F. Smyth' 2, D. Schol3 & J. Hilgers3
'Inperial Cancer Research Fund Medical Oncology Unit,
2University Department of Clinical Oncology, Western
General Hospital, Edinburgh, UK and 3Netherlands Cancer
Research Institute, Amsterdam, The Netherlands.
The immunological characterisation of 9 ovarian carcinoma
cell lines was undertaken to determine if antigen expression
might correlate with differentiation status in this disease. Six
lines derived from poorly differentiated adenocarcinomas
(PD) were compared with 3 lines derived from a patient with
a well differentiated serous adenocarcinoma (WD).
Cells were air dried onto multispot slides and
acetone/methanol fixed. Mouse anti-human monoclonal
antibodies (MoAB) were applied followed by immuno-
peroxidase staining (PAP staining).
In the PD group, expression of the neuroendocrine antigen
123C3 and vimentin was low (<5% and <14% cells +ve
respectively) but increased in the WD lines (> 19% and
>51% cells +ve). Conversely expression of OC125 was high
in the PD lines (>51% cells +ve) and reduced in the WD
lines (<33% cells +ve). PE016 (a PD cell line) was
exceptional and possessed properties similar to the WD lines.
The MoAbs AUAI (anti-epithelial) and LE61 and CAM5.2
(anti-cytokeratin) reacted with almost all cells in all cell lines
(except for PE016) as did anti-CEA. HMFG1 and HMFG2
were present in all cell lines (% varying between 10% and
87%).
MHC class I expression (MoAb 92.1) was present in 2/9
cell lines and Class II expression (MoAb CR343) in 6/9 lines.
Anti-placental alkaline phosphatase MoAbs (H17E2, 3F6,
I IF7 and 8B6) reacted with 6/9 cell lines (I-9% cells +ve).
Therefore expression of 123C3 and vimentin appear to
correlate directly, and OC125 inversely, with serous
differentiation in these cell lines.
The clinical role of Ca 125 in ovarian cancer
J. Cassidy', M. Kerr', J. Roulston2 & R.C.F. Leonard'
1 University Department oJ Clinical Oncology, Western
General Hospital, Edinburgh and 2University Department of
Clinical Chemistry, Royal Infirmary oJ Edinburgh, UK.
Two hundred and thirty-six serum samples from 61 patients
with histologically proven ovarian carcinoma were analysed
for Ca 125 level using a commercial IRMA assay (Centocor
Inc., Malvern, Pennsylvania, USA). The results of these
assays were correlated with clinical and radiological
(including ultrasound) assessments of disease status during
and after chemotherapy. Twenty-nine patients in the study
had a second-look laparotomy; in 21 patients pre-operative
levels of Ca 125 are available. The upper limit of normal
Ca 125 was taken as 35 U ml- 1. In patients who did not have
second-look surgery, a true negative result was defined as a
period of 6 months off therapy without evidence of
recurrence. Overall our results give 60.5% sensitivity, 91.3%
specificity and 66.5% accuracy. The levels of Ca 125 showed
a correlation with disease progression or response in 64.7%.
Of the 21 evaluable patients who had a second-look
laparotomy; no patient had a positive Ca 125 result with a
subsequent negative laparotomy. Second-look surgery could,
therefore, have been avoided in 6/21 cases (28.6%) on the
basis of elevated Ca 125. In 21 patients assays were
inconsistent over time due to false negatives. In I I the
fluctuations were wide, but in 10 could be explained by the
inherent imprecision of the assay at antigen concentrations
of < 100 U ml - 1. It is our conclusion that serum Ca 125
assay is a useful marker in ovarian carcinoma, and may be
of value in the avoidance of unnecessary second-look
surgery.
An assessment of urinary polyamine excretion in the
management of patients with epithelial ovarian cancer
F.G. Lawton', M. Griffin2, J.A. Slack2 & G. Blackledge3
'Departments of Obstetrics and Gvnaecology and 3Medicine,
University ofBirmingham and 2Institute of Pharmaceutical
Sciences, University of Aston, UK.
Urinary polyamine (UPA) excretion patterns have been
shown to correlate with a number of clinical parameters
including disease bulk, remission status, clinical course of the
disease and prediction of relapse in a variety of
malignancies, but little data are available relating their role
in the management of patients with epithelial ovarian cancer.
The polyamines (PA) (putrescine, spermidine, spermine
(put, spd, spm)), their acetylated derivatives (ACPA) (acput,
acspd, acspm) and total UPA (totput, totspd, totspm,
totupa) levels were measured in random urine samples by
HPLC (Spragg & Hutching, J. Chromatogr., 258, 289, 1983)
in 43 control subjects (group A), 15 patients (pts) with
benign pelvic masses (B), II pts with FIGO stage I disease
(C) and 57 pts with advanced EOC (D).
Depending on the UPA specified, between 1 and 7
(median 2) of 58 normal pts (A and B combined) had levels
above the upper limit of normal (false positive rate 2 to 13%)
while true positive rates varied from II to 30%. Overall
46% of pts with EOC had at least one raised UPA level.
There were significant differences in pre-laparotomy levels
of ACPA in patients with benign and malignant pelvic
masses.
A single UPA was raised in only I of 5 pts with well
differentiated EOC compared with 4 of 10 pts with moderate
differentiation and 12 of 15 with poorly differentiated
tumours.
Comparison of paired UPA levels over a 5 to 6 month
period showed significant increases in put, acput and totput
for pts with progressive disease and significant falls for pts
with responding disease.
Chemotherapy (CT) produced rises in UPA excretion in
49% (for totspd) to 79% (for put) of pts within 48 hours of
treatment.
The ratio UPA 48 hrs post-CT/UPA pre-CT was
significantly higher for pts who would eventually respond to
CT compared with those who would not for spd, acput,
acspd, totput, totspd and totupa.
UPA excretion can aid the differential diagnosis of pelvic
masses, reflects tumour bulk and differentiation and can
predict ultimate response to chemotherapy in pts with EOC.
Tamoxifen in a loading dose schedule in refractory ovarian
cancer
R.J. Osborne', M.L. Slevin', V.J. Harvey2, J. Shepherd3,
S. MalikI & C.J. Williams4
'ICRF Department of Medical Oncology, St Bartholomew s
and Homerton Hospitals, London, UK, 2Department oJ
Clinical Oncology, Auckland Hospital, New Zealand,
3Department of Gynaecology and Oncology, St Bartholomew's
Hospital, London and 4CRC Medical Oncology Unit,
Southampton, UK.
Reports of substantial activity for tamoxifen in refractory
ovarian cancer have led to widespread use, particularly
because of the drug's low toxicity. However, despite initial
enthusiasm, several studies have failed to observe anySECOND ANNUAL MEETING OF THE ASSOCIATION OF CANCER PHYSICIANS
activity. It is possible that the delayed achievement of
therapeutic levels of tamoxifen might permit early tumour
progression. The activity of a loading dose schedule known
to rapidly achieve stable therapeutic levels of tamoxifen has
therefore been investigated in refractory ovarian cancer.
Forty-six previously treated patients (mean age 61 yrs,
median Karnofsky performance 80%) with stage III or IV
measurable ovarian cancer were treated with tamoxifen,
100mg m-2 day 1 and 40mgday- I thereafter. Treatment
was continued until there was unequivocal evidence of
progressive disease. Forty-four patients were assessable for
response. There was one partial remission lasting 3 months.
Forty patients progressed within 4 months of treatment, 3
patients progressed within 6 months of treatment. Median
survival from commencement of tamoxifen was 4 months.
No significant toxicity occurred. It is concluded that the
activity of tamoxifen in refractory ovarian cancer is minimal.
Age as an independent prognostic variable in cervical cancer:
Survival analysis of 10,018 cases
C. Meanwell, S. Wilson, K. Kelly, C. Roginski &
G. Blackledge
West Midlands CRC Clinical Trials Unit and Birmingham and
West Midlands Region Cancer Registry, UK.
Recent regional and national data indicate that there has
been an increase in invasive cervical cancer registration and
death rates in young women (<40 years). Evidence from a
number of sources suggest that this group carries a worse
prognosis than older women with the disease. The aim of
this study was to determine whether youth is an independent
and unfavourable prognostic factor, particularly in women
diagnosed since the early 1970s. Data were taken from the
case-notes and from computerised records of 10,018 women
with invasive cervical carcinoma resident within the West
Midlands region at the time of diagnosis between 1957 and
1981. Detailed manual and computerised data validation was
performed before analyses to ensure completeness and
precision of data. Univariate and multivariate survival
analyses were performed using a number of patient variables
including year of diagnosis, age, duration of symptoms, site
of primary tumour, size of primary tumour, clinical stage,
histology, presence and site of lymph node and metastatic
disease and treatment. Cox regression analysis of survival
identified clinical stage, lymph node status, age group and
histology as independent prognostic variables. After
controlling for other variables, there was a positive
association between age and hazard of death from cervical
cancer. Using the model, a selection of estimated survival
functions were computed. These indicate that in all years,
youth was a significant and favourable prognostic factor.
Active chemotherapy in the treatment of advanced and
recurrent cervical cancer
G. Constantine, C. Meanwell, G. Blackledge, J. Mould,
A. Chetiyawardana, D. Spooner, T. Latief, M. Patterson,
M. Sokal, C. Alcock, F. Lawton & J. Kavanagh
Clinical Trials Unit, Queen Elizabeth Hospital, Birmingham
B15 2TH, UK.
Forty-four patients with recurrent or disseminated cervical
cancer have been entered into a prospective trial of
bleomycin, ifosfamide and cis-platinum (BIP). Twelve further
patients have received this regimen prior to radiotherapy
(RT) in a neoadjuvant setting. In the group with recurrent
disease 32 have completed treatment and are evaluable for
response. Three of 32 were adeno- and 29/32 squamous
carcinomas. Sixteen of 32 had previously received RT alone,
6/32 radical surgery, 9/32 both, and 1/32 no previous
treatment. In the neoadjuvant group 6/12 had stage 2, and
6/12 stage 3 disease. Patients were treated with bleomycin
(30mg infused over 24h), followed by cis-platinum
(50mgm-2 bolus) and ifosfamide (5 gm-2 infused over
24h), with concomitant hydration (total 10 litres over 3
days) and mesna (8 g m -2 given during and for 12 h
following ifosfamide) for between 1 and 8 courses
(mean =4).
In the group with recurrent disease 23 (72%) objective
responses were seen. Seven women had a WHO complete
response, 6 confirmed by CAT scan. At least 700o of
patients noted a subjective improvement in disease related
symptoms. Seven patients went onto further RT to
consolidate the response. Response duration varied between
2 and 11 months with chemotherapy, alone (median 4
months). In the neoadjuvant group 9/12 (75%) had at least a
50% reduction in tumour bulk prior to RT. All patients
experienced alopecia and nausea/vomiting. Of the evaluable
patients 15 (34%) needed one or more blood transfusions
and 6 (14%) developed septicaemia. Eight (18%) developed
ifosfamide related confusion/disorientation but none were
severe. Only one of these was not predictable by the use of a
nomogram devised concurrently. Two patients developed cis-
platinum associated renal damage and there was 1 death
partially treatment related from septicaemia.
These data indicate that the BIP combination is highly
active in cervical cancer, and may be used for effective
palliation and tumour debulking in around 70% of patients
with advanced or recurrent disease. Based on these results a
multi-centre randomised trial has been launched to determine
whether neoadjuvant BIP improves survival in patients with
inoperable cancer.
Relapse following POMB/ACE chemotherapy: Importance of
treatment intensity
S.M. Crawford, E.S. Newlands, G.J.S. Rustin, R.H.J. Begent
& K.D. Bagshawe
Cancer Research Campaign Labs, Department of Medical
Oncology, Charing Cross Hospital, London W6 8RF, UK.
More than 90% of patients with germ cell tumours treated
initially with POMB/ACE (cis-Platin, Oncovin, Methotrexate,
Bleomycin, Actinomycin D, Cyclophosphamide, Etoposide)
achieve long term remission (Newlands et al., Br. J. Urolog.y,
58, 307, 1986). However, a small number relapse. In order
to investigate the effect of variation in the intensity of
treatment on the likelihood of relapse, we have conducted a
case control study.
Each of 15 patients who received POMB/ACE as their
initial chemotherapy and who eventually relapsed was paired
with a control who had comparable serum concentrations of
alpha fetoprotein and chorionic gonadotrophin and who was
treated at about the same time. Indices of chemotherapy
were calculated from the doses per m2 given divided by a
standard dose. Indices a and ,B describe the drugs whose
dose shows most individual variation, y and 3 the remaining
drugs. A patient receiving full dose POMB-POMB-ACE-
POMB-ACE-POMB-ACE-OMB in the first 4 months has
indices a= I and y= 1. Indices [1 and 6 were arbitrarily
derived from the mean dose received by the control patients.




y (treatment in first 4 months)
=(O/5 +B/150 +A/4.5 +C/1500)/4
i (subsequent treatment)
=(0/1.8+B/54+A/1.8+C/867)/4
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Using the paired t-test, cases vs. controls, a (P=0.015,
median ratio case: control =0.9) and f (P=0.035, median
ratio =0.7) were significantly less in the cases; the trend was
not significant in y (P=0.568) or 6 (P=0.617).
These findings are consistent with the view that sub-
optimum delivery of chemotherapy is a cause of failure.
An open randomized trial comparing zoladex 3.6mg depot
with stilboestrol 3mg day ' in advanced prostate cancer:
Patient characteristics, response and treatment failures
L.A. Emtage, C. Trethowan, C. Hilton & G.R.P. Blackledge
For the West Midlands Urology Research Group and at the
CRC Clinical Trials Unit, Queen Elizabeth Hospital,
Edgbaston, Birmingham, UK.
A large multicentre randomised study comparing zoladex
3.6mg depot with stilboestrol (DES) 3mgday-1 in patients
with locally advanced or metastatic carcinoma of the
prostate is reported. One hundred and twenty-eight patients
with previously untreated, histologically confirmed prostate
cancer T3 or greater, or any T, M1 have been entered to
the study. Prior radiotherapy, other previous malignancy,
and incipient spinal cord compression were exclusions.
Thirty-nine of 128 (30.5%) patients had a prior history of
cardiovascular disease. An analysis of baseline patient
characteristics was done to ensure that there was no bias in
the randomisation, and no significant difference was found
in the two groups when analysed by age, history of cardio-
vascular disease, time of diagnosis to time of treatment,
symptom status, T status, M status, abnormal haematology
or abnormal biochemistry, including acid phosphatase levels.
Follow-up on the first 77 patients at three months reveals
a partial objective response rate of 50% (±16%) for zoladex
and 52% (±20%) for DES. Subjective responses are also
similar for both groups. However 20 patients were
withdrawn from DES therapy compared to 4 from the
zoladex group due to adverse reaction. This difference is
statistically significant (X2 = 12.5, P<0.001). Two minor and
three major increases in bone pain were found after the first
zoladex treatment, compared to none on DES, but none of
these required treatment withdrawal. Two patients developed
spinal cord compression, one in each treatment group. Both
of these were successfully treated with radical radiotherapy
and did not require withdrawal from treatment. Insufficient
data is available at this stage for proper comparison of
duration of response and survival. From this group of
patients we show that zoladex is as effective as DES in the
treatment of advanced prostate cancer, but is better tolerated
than DES. Thirty per cent of these patients had a history of
cardiovascular disease, and zoladex is a useful alternative
therapy in this group of patients, who tolerate DES poorly.
Drug resistance and metabolism
Genomic rearrangements and differential expression in
radiation resistant L5178Y murine lymphoma cells
J. Lunec* & D.J. Sherratt
Institute ofGenetics, University ofGlasgow, Church Street,
Glasgow GIl 5JS, UK.
*Current address: Cancer Research Unit, University of
Newcastle-upon-Tyne, Royal Victoria Infirmary,
Newcastle-upon-Tyne NEJ 4LP, UK.
Isolates of genomic DNA and polyadenylated mRNA from
radiation resistant (L5178YR) murine lymphoma cell lines
and the sensitive parental line (L5178YS) from which they
were derived, were analysed for evidence of differential
expression and possible gene amplification. SDS-
polyacrylamide gel electrophoretic analysis of in vitro
translation products from mRNA preparations gave evidence
of differences in the pattern of gene expression between the
resistant lines and the sensitive parental line. In particular, a
polypeptide of -50K was synthesised at an elevated level
with mRNA samples from the L5178YR cell lines. Also,
when duplicate Southern transfers of genomic DNA digests
were hybridised with cDNA probes made by reverse
transcription from mRNA derived from L5178YS and
L5178YR3 (the most resistant line in the series), differences
in the banding pattern were obtained, in which identified
DNA fragments from genes transcribed at an elevated level
in the resistant line.
A further observation was that a transcribed repetitive
element, detected as a 4.9kb BglII band on blots of genomic
digests probed with total cDNA, was reduced in copy
number in the resistant lines compared with the sensitive
parental line. This reduction was also observed with
independently derived resistant lines. The possibility that this
is an inducible provirus in this system is being investigated.
The cloning of differentially expressed genes and those
involved in observed genomic rearrangements in this system
has been initiated.
A variant of the human lung carcinoma cell line A549 selected
for resistance to hydroxyurea
N.C.H. Kerr & A.L. Harris
Cancer Research Unit, University ofNewcastle-upon-Tyne,
Royal Victoria Infirmary, Newcastle-upon-Tyne NE] 4LP,
UK.
Non-mutagenised A549 cells were chronically exposed to the
ribonucleotide reductase inhibitor hydroxyurea (HU) at
stepwise increasing concentrations of drug over a period of
18 mo. Cells routinely cultured in 2mM HU were cloned and
5 that grew through 2.2mm HU were selected and grown up,
being designated A549NK-1 to -5. Clone NK-1 cells have
doubling times of approximately 33h in undrugged medium
compared with -22h for parental cells. In a standard 3
days growth inhibition assay, the ED50 for NK-1 cells was
2.4mM compared to a parental value of 120,uM HU, i.e. 20-
fold resistance to HU. Doubling times in drugged medium
for the NK-1 cells were 33h for up to 1mM-, 40h in 1.5mM-
and 52h in 3mM-HU. In clonogenic assays, the plating
efficiencies in undrugged medium were 0.6% for NK-1 cells
compared with 54% for parental cells. In drugged medium,
NK-1 cells gave a biphasic response with plating efficiencies
of 4% at 0.3-1 mM HU, indicating a dependence on drug for
optimal growth. Clone NK-1 cells are far less cross-resistant
to two other ribonucleotide reductase inhibitors, 3,4-
dihydroxybenzohydroxamic acid (Didox) and 3,4-dihydroxy-
benzoamidoxine. HCl (Amidox), being respectively 2.8- and
2-fold resistant. This low level of cross-resistance suggests a
changed conformation in the M2 subunit of the ribo-
nucleotide reductase in the HU-resistant cells. Karyotype
analysis of the NK-1 cells revealed a decrease in
chromosome numbers compared to parental cells, with a
marker chromosome possibly of homogeneously staining
region type, and an absence of double minutes. This is the
first report of a human cancer cell line selected for resistance
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Possible induction of pleiotropic drug resistance (PDR) by
single agent ifosfamide (Ifos) in children with untreated
advanced neuroblastoma (AN)
S.J. Kellie, J. Pritchard & J. de Kraker
European Neuroblastoma Study Group (ENSG), The Hospital
for Sick Children, Great Ormond Street, London WCIN 3JH,
UK.
Neuroblastoma is an uncommon malignancy and patients
(pts) with advanced disease have a relatively poor prognosis.
New agents are urgently needed but Phase III studies can
take a long time to complete because (a) 'experimental
therapy' is often not appropriate in children with recurrent
disease and (b) response rates in heavily pretreated pts are
often low. In 1984, therefore, the ENSG decided to measure
the response rate to single agents at diagnosis, moving on to
standard combination chemotherapy (CT) (OPEC;
vincristine, cis-platinum, etoposide, cyclophosphamide or a
variant) after 4-6 weeks. In ENSG study 3A, 35 treatment
courses of Ifos (3 gm-2 x2 with mesna) were administered
i.v. to 18 consecutively diagnosed pts (10 male) median age
2.8yrs, range 1.3-5.3yrs. The overall response to Ifos was
44% (8/18) using"'the response definitions of ENSG. Nine pts
(50%) had >50% reduction in the volume of primary
tumour. Of 15 pts with raised pre-treatment VMA excretion,
6 (40%) respond,d with >50% reduction. Ten pts were
evaluable for bone marrow response. Two pts (20%) had
complete clearance of bone marrow involvement. Toxicity
was mild in all patients.
Although the initial response rate to Ifos was encouraging,
only 4 pts (22%) were in GPR or CR at the completion of
'first line' therapy. Median survival was 9 months. In an
earlier study (ENSG 1) pts with AN having similar pre-
treatment characteristics who were treated with OPEC from
diagnosis had a median survival of 16 months. The
difference in median survival between the two studies cannot
be explained by dissimilar pts, staging procedures or
combination CT. Our data indicates Ifos is an active drug in
untreated AN and is associated with mild toxicity. The
shortened median survival compared with ENSG I is
unexplained, however, the induction of PDR with Ifos
cannot be excluded.
Extra-hepatic metabolism of cyclophosphamide: A mechanism
of differential tumour cell sensitivity?
M.C. Walker', I.C. Shaw2, & R.W. Masters'
phosphamide (a non-cytotoxic excretory product) was
generated by liver and bladder, but not by testis.
These findings support the hypothesis that differential
tumour sensitivity to CP may have a metabolic basis, and
also that extrahepatic metabolism is a possible mechanism of
prodrug activation.
Metabolic activation of the 8-(N,N-dimethylcarboxamide)
analogue of mitozolomide
K.R. Horspooll, A. Gescherl, C.P. Quaterman',
M.F.G. Stevens', & E. Lunt2
'CRC Experimental Chemotherapy Group, Pharmaceutical
Sciences Institute, Aston University, Birmingham and 2May &
Baker Ltd, Dagenham, Essex, UK.
Structure-activity studies on various derivatives of the
experimental anticancer agent mitozolomide (I) substituted
in the 8-carboxamide moiety have shown the requirement of
a N-H in this position for maximum cytotoxicity. For
example, the monomethyl (2) and dimethyl (3) derivatives of
(1) are equiactive with (1) against the TLX5 lymphoma in
the mouse in vivo. However, (3) is less cytotoxic than (2) or
(1) when incubated with TLX5 lymphoma cells in vitro
(IC50: (3) 14.6, (2) 3.0, (1) 2.3,M). In order to explain this
discrepancy between the high antitumour activity and the
low cytotoxicity of (3) its metabolism was studied in vitro.
The hypothesis for this investigation was that (3) undergoes
metabolic N-demethylation to the highly cytotoxic
compounds (2) and/or (1). Incubation of (3) (I0ptgml-1)
with mouse liver microsomes and TLX5 cells produced a
significant increase in the cytotoxicity of (3). The activation
was dependent on the presence of an NADPH-generating
system. HPLC analysis of the incubation mixture of (3) with
microsomes afforded a peak which co-chromatographed with
(2). The amount of (3) converted to (2) within 45min was
30%. This result suggests that the metabolic production of
(2) might account for the high antitumour activity of (3)










'Institute of Urology, St Paul's Hospital, London WC2, and
2Toxicology Laboratory, University College London, London
WCJ, UK.
Using cyclophosphamide (CP) as a model compound we
have investigated extra-hepatic metabolism in vitro. The
differential sensitivity of histologically distinct types of
tumour to anticancer prodrugs might be due to differences in
their ability, or that of surrounding normal tissue, to
metabolically activate these compounds. Traditionally, the
liver has been regarded as the site of prodrug activation.
Testicular tumour cells were more sensitive to the
cytotoxic effects of CP than bladder tumour cells, following
continuous exposure in a colony-forming assay. For
example, 1 mM CP killed -99% of clonogenic cells in a
testicular tumour cell line (833 K) studied, compared with
10% cell kill in a bladder cancer cell line (RT112). The
metabolites generated by incubation of normal rat tissue
homogenates with 1 mM CP were analysed by HPLC.
Phosphoramide mustard (PM) (a cytotoxic metabolite of CP)
was generated by bladder and testis, in quantities
comparable with that produced by liver. Carboxy-
The metabolic basis for the protective effect of feeding the
antioxidant, ethoxyquin, on the hepatocarcinogenic action of
aflatoxin B, in the rat
H.G. Mandel, G.E. Neal, M.M. Manson & D.J. Judah
MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM54EF, UK
The dietary administration of 0.5% ethoxyquin (EQ) has
been found to be strongly protective against the hepato-
carcinogenic effect of the simultaneous dietary
administration of aflatoxin B, (AFB1). EQ increases the
microsomal cytochrome P-450, resulting in an increased rate
of in vitro AFB1 metabolism and formation of the less toxic
AFBI metabolites, AFQ, and AFM1. The formation of the
active AFB,-epoxide is increased to a lesser extent. These
changes in metabolism are paralleled by the pronounced
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The cytosol-catalysed conjugation of AFB1-epoxide with
GSH is also greatly increased and the binding of['3H]-AFBI
to rat liver DNA in vivo reduced by EQ (70% inhibition 2h
after dosing with 1 mg AFB1 kg-1 body wt.). It is suggested
that the reduced DNA binding and hepatocarcinogenesis by
EQ treatment results at least in part from increased
detoxification in the endoplasmic reticulum and cytosol
compartments of the hepatocytes.
The adverse f-oxidation pathway is markedly inhibited with
novel p and y substituted analogues of chlorambucil
P. Workman', M. Oppitzl, J. Donaldson & P. Coe2
1MRC Clinical Oncology Unit, Cambridge and 2Department
of Chemistry, Birmingham University, Birmingham, UK.
The antitumour selectivity of chlorambucil, 4-[4-bis-(2-
chlorethyl)amino-phenyl]butyric acid (I), is thought to be
limited by metabolism through the f-oxidation pathway,
resulting in the accumulation of phenylacetic mustard
(PAAM). Thus inhibition of this pathway should lead to an
improved therapeutic index. We previously found support
for this hypothesis with the fl,f3-difluoro analogue (II) (Lee et
al., Cancer Chemother. Pharmacol., 17, 21, 1986). We now
show that metabolism to PAAM can be reduced further by
appropriate ,B and substitutions. Drugs were administered
i.p. to C3H/He male mice and plasma analysed by a
sensitive and specific isocratic, paired-ion reverse-phased
HPLC assay with u.v. analysis at 254 and 280 nm.
CICH2CH2 N P a CICH C HyNiJCH2CH2CH2COOH I
Structure Plasma
(PAAM) (ugml ')
Compound / ;, 30min 120min
I H,H H,H 14.7 8.9
Il F,F H,H 6.7 4.3
111 F,F F,F <0.6 <0.6
IV CH3,H H,H <0.3 not determined
V CH3,CH3 H,H <0.2 <0.2
VI CF3,H H,H <0.2 <0.2
The results show clearly that PAAM formation is markedly
reduced in all cases. These novel agents may afford a further
improvement over analogue II, and antitumour testing is
now under way.
Further evidence that flow cytoenzymological assay of cellular
esterase inhibition measures intracellular carbamoylation by
chloroethylnitrosourea-derived isocyanates
C. Dive, P. Workman & J. Watson
MRC Clinical Oncology and Radiotherapeutics Unit, MRC
Centre, Hills Road, Cambridge, UK.
Chloroethylnitrosoureas (CNUs) decompose in an aqueous
environment yjelding alkylating fragments and isocyanates.
While the former cross-link DNA, the latter carbamoylate
cellular proteins, a reaction implicated in DNA repair
inhibition. We recently reported a novel flow cyto-
enzymological technique for the measurement of intracellular
carbamoylation based on inhibition of cellular esterases by
CNUs. Intrinsic enzyme inhibition and cellular penetration
were shown to contribute to extent of inhibition. We now
report further evidence that this assay measures intracellular
carbamoylation by CNU-derived isocyanates. EMT6 mouse
mammary tumour cells were harvested in log phase and
exposed to test agents for 1 h, before analysis of esterase
kinetics on the Cambridge flow cytometer. Chloroethyliso-
cyanate, the decomposition product of BCNU, exhibited
inhibitory potency similar to the parent drug. The 150 value
(concentration to produce 50% inhibition) was 1.2x 10-4M,
compared to 2.0 x 10-4 M for BCNU. Values for CCNU and
its metabonate cyclohexylisocyanate were 7.0 x 10-4 M and
5.4 x 10- M respectively. Using conventional spectro-
fluorimetry with simple alkyl isocyanates, inhibitory potency
was in the order butyl > propyl >ethyl >methyl,
demonstrating a clear effect of alkyl chain length. The
alkylating agents nitrogen mustard and melphalan failed to
inhibit intracellular esterases at concentrations up to 10 -3 M.
Thus carbamoylating but not alkylating species cause
inhibition of the esterase reaction. Using this assay with
novel antitumour agents, we have obtained 150s of
8x10-4M for TCNU (similar to CCNU) and 1.5x10-3M
for temozolomide (slightly more potent than the related
mitozolomide), but minimal inhibition for clomesone and
cyclodisone.
Purification, photoaffinity labelling and characterisation of
a 4-5S rat cytosolic binding protein specific for
3-methylcholanthrene
P.S. Arnold, R.C. Garner & B. Tierney
Cancer Research Unit, University of York, Heslington, York
YO 5DD, UK.
Rat hepatic proteins which sediment at 4 to 5S on sucrose
gradients exhibit high affinity (2.5 nM), saturable
(700 fmol mg-1) binding for the carcinogen 3-methyl-
cholanthrene (3MC). A rat liver protein of Stokes radius
3nm, molecular weight by SDS PAGE of 39,000 and with
specific 3MC-binding activity sedimenting at 4.5S, has been
purified 315-fold to apparent homogeneity using affinity
chromatography on a column of l-hydroxy-3-methyl-
cholanthrene (I-OH-3MC) coupled to epoxy-activated
sepharose 6B, in conjunction with two gel filtration steps.
The protein purified by this technique was shown to be
associated with the observed specific 3MC binding activity
by photoactivation using 3-methylcholanthrene-I-one (3MC-
1-one). This purified specific 3MC binding protein appears
to consist of two or more isozymes (pl 6.1 and 6.2) on 2-
dimensional SDS PAGE, and has been characterised with
respect to its amino acid composition, its specificity and
capacity for binding 3MC. This binding activity has been
associated with a regulatory disulfide group on the protein.
In addition to characterisation, several monoclonal
antibodies have been prepared against this protein.
Immunocytochemical localisation of VP16 in normal and
malignant tissue
H.P. Henneberry & G.W. Aherne
Department ofBiochemistry, Universiti' ofSurrev', Guildf6rd,
Surrey, GU2 5XH, UK.
The peroxidase anti-peroxidase (PAP) technique of immuno-
cytochemistry has been used to visualise the distribution of
the cytotoxic drug VP16 in fresh-frozen and fixed tissues
from normal and tumour-bearing animals. Tissues were
obtained from normal mice at various times after high and
low dose VP16. Semi-quantitative measurement of intensity
and distribution of immunostaining correlated with tissue
and plasma concentrations of VP16 measured with ELISA.
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VP16 at 1 hr after a I mgkg - dose. Corresponding tissue
levels of VP16 were 7.8, 5.7, 2.4, 2.0 ggg-1 in kidney, heart,
small intestine and liver respectively and 2.0,igml - 1 in
plasma. The highest dose of VP16 tested (80 mgkg - 1)
produced very intense immunostaining in all organs,
corresponding, at 1 hr after dosing, to tissue levels of 828,
678 and 136 gg- 1 in small intestine, kidney and liver
respectively. Inter animal variations in tissue concentrations
and in immunostaining were minimal.
L1210 leukaemic mice showed increased hepatic
accumulation of VP16 and different renal and small
intestinal distributions of VP16 compared to normal mice.
VP16 immunostaining was also demonstrated in sensitive
and multi-drug resistant murine mammary tumour (EMT6)
sections (supplied by Dr P. Twentyman). Three of 4 parent
tumours examined had positive VP16 immunostaining. Two
of 4 resistant tumours also showed some positive immuno-
staining but this was less intense than in the parent tumour
sections. Compared to uptake of VP16 in organs, drug
uptake in this tumour type was poor. These results suggest
that immunocytochemistry may be a useful technique for
studying the distribution of drugs given singly or in
combination, specific organ toxicities and mechanisms of
resistance.
Induction of glutathione S-transferase P in liver and kidney
M.M. Manson', J.A. Green', S.A. Griffiths', J.L. Simpson'
& C.A. Power2
'MRC Toxicology Unit, Woodmansterne Road, Carshalton,
Surrey SM5 4EF, UK. and 2Ciba Geigy Ltd, Postfach
CH-4002, Basel, Switzerland.
Glutathione S-transferase P (GST-P, 7-7 form) is normally
present in rat kidney but not in hepatocytes. Its induction
has been described in preneoplastic lesions and tumours
where it is considered by some to be a more specific marker
for carcinogenesis than glutamyl transpeptidase, which can
be induced by many non-carcinogens in a non-focal manner.
Using a cloned probe for GST-P (Sugioka et al., Nucleic
Acid Res., 13, 6049, 1985), we have shown induction of
mRNA, not only in AFB,-treated liver, but also in a normal
liver-derived cell line (BL8) and in primary hepatocytes after
48 h in culture. BL8 cells showed a greatly enhanced
induction of GST-P after treatment with AFB, or
transfection with an active ras oncogene (Sinha et al., Cancer
Res. 46, 1440, 1986). Using polyclonal antiserum (donated
by Dr T. Rushmore, University of Toronto) we have shown
immunohistochemically that AFB, treatment (1 ppm, 17wk)
induced 2.5 x as many GST-P positive foci as were
visualised by GGT histochemistry. Ethoxyquin (0.5% in
diet) in combination with AFBJ prevented focal formation,
but induced GST-P periportally. In addition to cytoplasmic
enzyme activity, many nuclei were also stained. EQ, with or
without AFB, induced GST-P in kidney, but in damaged,
hyperplastic or preneoplastic tubules the activity was
sometimes low or absent. Variable levels of GST-P were also
found in preneoplastic tubules and adenomas resulting from
a single injection of dimethylnitrosamine (40mgkg-1). Thus
while high levels of induction of GST-P appear to be
associated with transformation in the liver, this is not
necessarily the case in kidney.
Differential expression of glutathione transferases in lung
tumour samples
J. Carmichael', A. Lewis', J.D. Hayes2, D. Lamb3 &
C.R. Wolf'
lICRF, Laboratory of Molecular Pharmacology and Drug
Metabolism, Edinburgh, 2Department of Clinical Chemistry,
Royal Infirmary, Edinburgh and 3University Department of
Pathology, Edinburgh, UK.
The glutathione S-transferases play a central role in the
detoxification of electrophilic chemicals and drugs and there
is a growing body of evidence which indicates that they play
an important role in resistance of tumour cells to a variety
of anticancer drugs. As part of an interest in the regulation
of glutathione-dependent enzymes in tumours we have
investigated glutathione transferase (GST) expression in a
range of normal and tumour lung specimens. Samples of
normal and lung tissue were taken from 10 patients
undergoing thoracotomy. GST activity was estimated using 3
substrates, CDNB, ethacrynic acid and trans-stilbene oxide.
Large variation in GST activity was observed between both
lung and tumour samples. GST activity in tumour samples
was expressed as a percentage of normal lung activity in
each patient. It was extremely interesting that the ratio of
GST activity of tumour to normal tissue reflected the
tumour type. CDNB activity was elevated 10 fold in the one
adenocarcinoma sample and 3-fold in 5 squamous carcinoma
samples compared to normal lung. No increase was observed
in small cell or large cell anaplastic carcinomas, however.
Differences in activity using ethacrynic acid as a substrate
were also observed, although these differences did not reflect
tumour type. Western blotting showed that all the samples
tested contained a considerable amount of the placental
(acidic) FST, although the level of this sub-unit did not
explain the differences in overall tumour activity. Initial
studies indicate the changes in tumour GST expression was
due to altered expression of the neutral sub-unit. The above
data indicate that study of GST isoenzymes could prove to
be a valuable tumour and prognostic marker in cancer
therapy.
Lung cancer and lymphoma
Prognostic factors in small cell lung cancer: A simple
prognostic index is better than conventional staging
M.D. Vincent, S.E. Ashley & I.E. Smith
Lung Unit, Royal Marsden Hospital, Sutton, UK.
Conventional staging (CS) in small cell lung cancer (SCLC)
is costly, complex, invasive and imperfectly prognostic. We
have therefore compared CS with a simple system using
presentation features identified by uni- and multi-variate
analysis as prognostically important.
Univariate analysis; prognostic significance in 333 patients
(1978-1985): P<0.00005, plasma albumin, marrow biopsy,
Performance Status (PS); P<0.001, plasma bilirubin, liver
scan (U/S or isotope); P<0.01, plasma Na+, gamma GT,
alanine transaminase (ala T.) alk. phos.; P<0.05,
haemoglobin, supraclavicular node, mediastinum, contra-
lateral lung.
Non-significant factors included SVC obstruction, pleural
involvement, age sex, WBC and platelets. Multivariate
analysis (proportional hazards) identified only plasma
albumin, ala. T, liver scan and PS as independently
prognostic (P<0.05). For simplicity, liver scan was excluded
with little effect on prognosis and a prognostic index (PI)
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>36gl-1; normal ala T.; PS=0/1 (37% patients). Group 2
('medium'): Up to 2 of: albumin =30-35g1 '; PS=2;
abnormal ala T. (41% patients). Group 3 ('bad'): The rest
(22% patients).
One year survival (50% 'good'; 27% 'medium'; 3% 'poor')
compares well with CS data of 48% for limited disease (LD)
and 18% for extensive (ED). Twenty-six per cent of ED
patients are in our 'good' prognosis group and 8% of LD
patients are in our 'bad' group. Our index gives more
detailed prognostic information than CS; it is simpler,
cheaper and less invasive.
Increased detection of micrometastases in the bone marrow of
small cell lung cancer (SCLC) patients
F.G. Hay', A. Ford2 & R.C.F. Leonard'
'Department ofClinical Oncology and 2Department of
Haematology, Western General Hospital, Edinburgh,
EH4 2XU, UK.
Rapid and accurate detection of metastases in the bone
marrow of patients with SCLC has important therapeutic
implications. Analysis of bone marrow is done routinely by
conventional histological examination of marrow smears
which has a good detection rate where foci of tumour cells
are present or large numbers of cells infiltrate the marrow
but is less satisfactory where single cells are sparsely
distributed throughout the marrow. We report on a series of
18 bone marrows from SCLC patients that were assessed for
tumour infiltration in several different ways - routine
histology; cytospin preparations of red cell depleted marrow
with immunohistology using 2 MoAbs (HMFG2, CAM5.2);
detailed examination of multiple air dried preparations of
red cell depleted bone marrow with a panel of 10 SCLC-
associated MoAbs and capacity to grow in serum-free
defined media (Hites). In 4/18 cases the routine marrow
examination revealed tumour infiltration and in 6/18 of the
cytospin preparations tumour cells were seen. Using the
larger panel of MoAbs a further 9 cases were thought
suspicious of tumour involvement although only isolated
cells were detected. In 8/9 of these we sustained growth of
cells morphologically similar to the putative tumour infiltrate
in Hites medium for periods of 1-18wks and 2 remain viable
as established cell lines. These results indicate that detailed
analysis of bone marrow using a panel of MoAbs may be
worthwhile particularly in programmes utilising autologous
marrow rescue as intensification therapy.
Randomised comparison of treatment duration in small cell
lung cancer (SCLC)
H. Earl', R.L. Souhamil, C.M. Ash', S.G. Spiro2,
D. Geddes3, P.G. Harper4 & J.S. Tobias'
'Department ofRadiotherapy and Oncology, University
College Hospital, London WCJ 6AU, 2Brompton Hospital,
London SW3 6HP, 3London Chest Hospital, London E2 9JX
and 4Guy's Hospital, London SE] 9RT, UK.
Six hundred and fourteen patients with SCLC entered a
randomised trial comparing different initial treatment
durations, and the value of chemotherapy on relapse.
Patients were stratified according to stage (limited or
extensive), and randomised to receive either 4 or 8 courses of
chemotherapy (cyclophosphamide 1 gm-2 day 1, vincristine
2mg day 1, etoposide 100mgtds days 1-3), 3 weekly. At
presentation patients were also randomised for treatment at
relapse, either to receive further chemotherapy (adriamycin
50mgm 2, and methotrexate 50mgm 2, every 3 weeks) or
symptomatic treatment alone.
Response rates to short (S) and long (L) initial chemo-
therapy were the same (S=64%, L=64%), as were response
rates to relapse chemotherapy (S=26%, L=22%). Overall
median survival (MS) was slightly better in patients receiving
8 rather than 4 courses of chemotherapy (MS 39 vs. 33
weeks, P=0.05). Progression free interval (PFI) was longer
in patients receiving 8 courses (median PFI 8 vs. 4 courses,
31 vs. 23 weeks, P=0.0001). Survival from relapse was
longer for patients receiving relapse chemotherapy than for
those receiving symptomatic treatment alone (MS 17 vs. 12
weeks, P=0.00001). The only treatment strategy associated
with a significantly worse survival was short initial
chemotherapy and no chemotherapy on relapse (MS 30 vs.
39 weeks, P=0.008). Other treatment strategies gave equal
results.
Randomised trial of planned versus as required chemotherapy
in small cell lung cancer (SCLC)
R.L. Souhamil, H. Earl', C.M. Ash', S.G. Spiro2,
D. Geddes3 & P.G. Harper4
'Department ofRadiotherapy and Oncology, University
College Hospital, London WCJ 6AU, 2Brompton Hospital,
London SW3 6HP, 3London Chest Hospital, London E2 9JX
and 4Guy's Hospital, London SE] 9RT, UK.
Patients with SCLC with poor prognostic features (Souhami
et al., Cancer Res., 45, 2878, 1985) have been treated in a
continuing trial of chemotherapy employing 2 different
approaches to treatment. Following an initial cycle of
chemotherapy (cyclophosphamide 1 gm-2 day 1, vincristine
2mg day 1, etoposide 100mgbd days 1-3) patients with
responding or stable disease are treated with the same
chemotherapy in one of two ways. One group receives
chemotherapy in planned 3 weekly cycles, the other receives
chemotherapy only when there is disease progression:
patients with responding or stable disease who are asymp-
tomatic are not treated but are seen every 3 weeks and
reassessed. One hundred and five patients have been
randomised up to November 1986. In the 'as required' arm
the median treatment-free interval between course 1 and
course 2 was 47 days; course 2 and 3: 44 days; course 3 and
4: 46 days; course 4 and 5: 44 days. These intervals are over
twice as long as the 'planned' chemotherapy. So far there is
no difference in survival in the two arms. Quality of life
assessments of the two forms of treatment are in progress.
This trial represents a new approach to palliative treatment
of SCLC.
A randomised trial of short courses of intravenous
chemotherapy versus oral out-patient chemotherapy for small
cell lung cancer (SCLC)
B. Cantwell', P. Corris2, J. Bozzinol & A.L. Harris'
North East Lung Cancer Group, ' University Department of
Clinical Oncology, Newcastle General Hospital and 2Chest
Unit, Freeman Hospital, Newcastle on Tyne, UK.
A regional trial comparing short- courses of i.v. chemo-
therapy given in hospital with out-patient chemotherapy
for SCLC was activated in March 1984 and 215 patients
have now been entered. Eligibility criteria included histo-
logically and/or cytologically proven SCLC, assessable
disease and WHO performance status <2. Patients were
stratified by extent of disease. Course 1 i.v. chemotherapy
was doxorubicin 40mgm2, vincristine 2mg, VP16
100mgm-2 i.v. and 300mg p.o. on days 2 and 3. Courses
2, 3 and 4 were doxorubicin 30mgm 2, vincristine 2mg,
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5 gm-2. Oral chemotherapy was chlorambucil 6mgm-2
daily, procarbazine 50mg t.d.s. and E.C. prednisolone 10mg
b.d., all for 10 days with VP16 300mg daily on days 1, 2
and 3. Both i.v. and oral chemotherapy were given every 3
weeks to a total of 4 courses, after which prophylactic
cranial and consolidation chest radiotherapy was given to
good responders, in both arms. Analysis of survival up to a
maximum of 32 months in the first 150 patients entered
shows highly significant survival advantage to 103 limited
stage vs. 47 extensive stage patients (P<0.01, log rank test).
There were no significant differences in survival between 76
i.v. and 74 orally treated patients overall or when subdivided
by stage. Interim analysis indicates that oral out-patient
chemotherapy confers similar early survival benefit to more
expensive hospital based i.v. chemotherapy.
First-line chemotherapy re-challenge after relapse in small cell
lung cancer
M.D. Vincent, B.D. Evans & I.E. Smith
Lung unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Conventionally, relapsed SCLC patients are offered
alternative, allegedly non cross-resistant chemotherapy (CT).
To question the assumption that these cancers are resistant
to their initial CT, we re-challenged 15 SCLC patients who
had relapsed off treatment with the identical regimens used
at induction. Presentation mean age was 63 years (yrs)
(57-73 yrs) and 7 had extensive disease (ED). At re-challenge,
13 had ED and 3 were ECOG performance status (PS) 1, 7
were PS 2 and 5 were PS 3. Thirteen were male. Three CT
regimens were used as follows:
Regimen 1 (10 patients): carboplatin (C) 300mgm-2 i.v.
day 1, etoposide (VP16) 100mg m-2 i.v. days 1-3, q. 28
days x 4 cycles.
Regimen 2 (3 patients): adriamycin (A) 40mgm-2 i.v. and
vincristine (V) 2mg i.v. day 1; VP16 100mgm-2 i.v. days
1-3, q. 21-28 days x 4 cycles.
Regimen 3 (2 patients): C 400mgm2 q. 28 days x 5 cycles
(1 patient) and C 800mgm 2 q. 28 days x 2 cycles (1
patient).
Ten of 15 patients (66%) achieved a second response as
follows:
First Second
Regimen Drugs Patients responses responses
I C,VPI6 10 4DR, 6PR 6PR
2 A,VP16,V 3 2CR, IPR 2PR
3 C 2 OCR, 2PR 2PR
Median response duration was 3 months (2-4). Responses
were more durable if first responses had lasted >8 months;
extent of first response had no influence on length of second
response. Relapsed SCLC has a good chance of responding
to first-line re-challenge CT, although responses are
temporary and incomplete. This indicates that relapse is not
entirely a consequence of emergent drug resistance, and
questions the concept of non-cross resistant CT.
Do some patients never require treatment for advanced low
grade non-Hodgkin's lymphoma?
M.E.R. O'Brien1, P. Easterbrooke2, I.C.M. MacLennan3,
J.M. Holt4, G.R.P. Blackledgel & R.C.F. Leonard5
1CRC Clinical Trials Unit, Queen Elizabeth Hospital,
Birmingham, 2Department ofMedicine, St George's Hospital,
London, 3Department ofImmunology, University of
Birmingham, 4Lymphoma Clinic, Churchill Hospital, Oxford
and 5Department of Clinical Oncology, Edinburgh, UK.
One hundred and eighty-two patients with low grade non-
Hodgkin's lymphoma (NHL) were analysed to study the
natural history of the disease. Median follow up 70mths
(range 18-199).
Sixty-nine patients had been allocated treatment according
to the presence or absence of B symptoms (Stage I excluded)
in a randomised trial. The remaining 113 were managed
using a watch and wait policy in the absence of symptoms or
rapidly progressing disease (Stage II - 18, Stage III - 44,
Stage IV - 92).
Fifty-six patients received no treatment at the time of
diagnosis. Of these 23 were allocated the no treatment arm
of a 'no treatment vs. chlorambucil' randomisation (B
symptoms excluded), the other 33 received no treatment by
attending physicians' choice.
Eleven of 23 and 11/33 have not yet required systemic
treatment, median follow up 70mths (range 18-199).
This group of never-treated patients had no special
characteristics in terms of age, sex, presenting symptom,
pathology or sites of involvement and did not differ from the
patients who later required treatment except Stage IV disease
was more common in the latter group P=0.03. Median time
until treatment was required 39mths (range 4-108 mths)
patients. The treatment free interval is similar to that
reported by the Stanford group (1984) but survival is
significantly different, 49% 5 year survival (confidence
intervals 34-64%).
From this we conclude there are no established prognostic
variables which will characterise low grade NHL patients
who will never need treatment but by adopting a policy of
initial no treatment in this group, at least 14% (22/154) of
patients may never require treatment.
Phase II and Phase III studies of weekly chemotherapy for
high-grade non-Hodgkin's lymphoma - A new regime
(CAPOMEt)
N.S.A. Stuart, J.A. Child, G.R.P. Blackledge,
A.V. Simmons, J. Fletcher, D.L. Barnard, M.H. Cullen &
L.A. Parapia
For the Central Lymphoma Group (Co-ordinating Centre,
CRC Clinical Trials Unit, Queen Elizabeth Hospital,
Birmingham, UK).
Recent studies have suggested that short-course weekly
chemotherapy (CT) may produce a higher complete response
(CR) rate in high-grade non-Hodgkin's lymphoma (HG-
NHL) than standard cyclical CT and may lead to increased
long-term survival. We have treated 28 patients (pts) with
HG-NHL and 5 with 'aggressive' low-grade NHL with a
weekly CT regime (CAPOMEt) comprised thus: Week l,
CA =cyclophosphamide 400mgm-2 +adriamycin 50mgm-2
both i.v. day 1. Week 2, P01 =vincristine 2 mg i.v. day
I +prednisolone 60mgm -2+ranitidine 150mgb.d. both p.o.
days 1-5. Week 3, MEt=methotrexate 250mgm -2 +etoposide
lOOmgm-2 both i.v. day 1 +etoposide 150mg p.o. days
2 and 3+oral folinic acid 15mgqds p.o. days 2-5. Week 4,
P02 as week 2. The regime repeats for 13 treatments, or if
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case ending with CA. Whenever possible CT continues
weekly with dose reduction for myelosuppression rather than
delay. Pt characteristics were as follows: mean age 54 (15-74),
Stage IV 19/30, bone marrow involved 5/32.
Mean doses given were as follows: C, 365 mgm 2; A,
45mgm -2; P, 58mgday-1; 0, 1.9mg; M, 226mgm-2; Et,
400mg (i.v.+p.o.). M and Et were the drugs most often
modified; number of times on which less than 75% of
protocol dose was given were: M, 15/75; Et 22/74; C, 15/88;
A, 14/88; P, 9/141; 0, 7/141. In all 82/608 (13%) of
treatments were modified. The commonest reasons for dose
modifications were leucopenia (18/56) and the patients' age
or poor general condition (13/46). Mean days delay for each
part of the cycle were CA, 1.3; PO1, 0.4; MEt, 1.2; P02, 0.2.
In all 32/276 (11 O%) of treatments were delayed. The
commonest reason for delay was leucopaenia (11/32). Mean
WBC (neutrophils) x 1091 1 prior to each phase of treatment
were: CA, 8.1 (5.3); PO1, 4.7 (3.1); MEt, 6.1 (3.6); P02, 4.7
(3.3) Grade 4 thrombocytopaenia was seen on only 4
occasions. Other toxicities experienced were: severe
neuropathy, 2/31; mucositis, 5/31; septicaemia, 3/31; chest
infections, 8/31; blood transfusion for anaemia, 8/31. There
was one death to which treatment contributed. CT was
continued to 16 weeks in 10 pts, to 12 weeks in 10 pts and
was stopped before 12 weeks because of toxicity in one and
because of death or disease progression in 10. CR rate for
HG-NHL was 67% (95% C.I. 48%-86%).
Toxicity of this regime is acceptable and mainly comprises
neutropaenia. CT can be given weekly on the majority of
occasions. MEt was the treatment most often modified but
in view of the blood counts 7 and 14 days later many of
these modifications may have been unnecessary. We have
begun a multi-centre, prospective, randomised trial
comparing CAPOMEt with standard cyclical CT (CHOP-
MTX). Major end-points will be toxicity, response rates, and
long-term survival. Forty pts have been randomised in the
first 6 months of the study which should end in 3 years.
Antiemetics
A randomised trial of oral nabilone and prochlorperazine
compared to intravenous metoclopramide and dexamethasone
in treatment of emesis induced by chemotherapy regimens
containing cis-platin of cis-platin analogues
D.Cunningham'2, C.J. Bradley', C.J. Forrest',
A.W. Hutcheon3, L. Adams', M. Sneddon2, M. Harding',
D.J. Kerr', S.B. Kaye' & M. Soukop2
'Glasgow UniversitY, Department of Medical Oncology,
2Department of Medical Oncology, Glasgow Roycal Infirmary
and 3 Woodend General Hospital, Aberdeen, UK.
Seventy-nine patients entered this randomised, open, cross-
over trial. All were receiving their first course of
chemotherapy with regimens containing cis-platin of cis-
platin analogues. Nabilone (N) 2mg and prochlorperazine
(P) 5 mg were given orally beginning 6 h before
chemotherapy and continued 12 hourly for 3 or 4 doses.
Metoclopramide (2mgkg- ') (M) was given as i.v. loading
dose, followed by i.v. infusion (3mgkg- 1) over 8h after
chemotherapy, combined with dexamethasone (D) 20mg i.v.
over 3-5 min at the time of chemotherapy.
With N and S there was complete control of vomiting in
23 patients (31.5%) (median number of episodes of vomiting
3.45+0.78) compared to complete control of vomiting in 40
patients (55.6%) treated with M and D (median number of
episodes 3.92+0.54) (P<0.05). Eighteen patients (25.4%) on
N and S did not feel nauseous, compared to 26 patients
(36.1 %) on M and D. The score of nausea on a linear
analogue scale was significantly better (P=0.018) with M
and D. With regard to toxicity, sedation was more frequent
with N and P (P<0.01) as was dryness of mouth (P<0.001)
and dizziness (P<0.001). Extrapyramidal reactions were
more common with M and D (P<0.001). Dysphoria
occurred in 20% of patients given N and S (but this was
severe in only 4.10%) and in 2.6% of patients given M and
D. There was no overall patient preference for either
antiemetic. (N and P=27; M and D=29; 12 no preference).
For patients receiving cis-platin, M and D is a more effective
antiemetic than N and P and is associated with fewer side
effects.
Comparison of the antiemetic efficacy of domperidone,
metoclopramide and dexamethasone in out-patients receiving
chemotherapy
D. Cunningham', C. Evans', A. Pople'2, J. Dearling',
D. Chappell'2 & R.C. Coombes'"2
'Medical Oncology Unit and 2Luditig Institute for Cancer
Research, St George's Hospital Medical School, London
SWI7 ORE, UK.
Sixty consecutive patients receiving out-patient
chemotherapy regimens without cis-platin entered the trial.
Five had received previous chemotherapy. There was pre-
randomisation stratification into regimens of high and low
emetogenic potential, before patients were allocated to I of 3
antiemetics. Domperidone (D) 20mg tds or metoclopramide
(M) 20 mg tds were given orally on the day before
chemotherapy and continued for 3 days with 20mg bd in
day 4 and 20mg on day 5. On the day of chemotherapy the
second dose of M was given as an i.v. bolus. Dexamethasone
(Dex) was given orally 4mg tds on the day before
chemotherapy and continued for 3 days with 4mg bd on day
4 and 4mg od on day 5. On the day of chemotherapy the
second dose was given as an i.v. bolus. If the first regimen
failed to control nausea and vomiting, patients were
randomly allocated to one of the remaining regimens, and if
that failed they were allocated to the third regimen.
There was complete control of nausea (N) and vomiting
(V) in 5 (25%) of the patients given M compared to 8 (40%)
with D and 12 (60%) with Dex. V was significantly less with
Dex compared to M (P=0.005), but other comparisons were
not statistically significant. After failing first-line antiemetic
treatment 3 patients were given M as a second option but all
experienced N and V. Also, 3 patients given D as a second
option experienced V. No patient was given M or D as a
third option. Six patients were given Dex as a second option
and only I experienced N and V. Of 2 patients given Dex as
aI third option 1 experienced N and V. Side effects profiles
were similar for each antiemetic including dyspepsia. Thrcie
were no recorded extra pyramidal reactions. Dex is a
superior antiemetic to M and may also be effective for
patients who fail to respond to D.
p endorphine - a modulator of emesis in patients receiving
chemotherapy?
G.J. Forrest2, D. Wallace2, D. Cunningham2, T. Young',
Y. Perry2, C. Gray2, F. Ballantyne2, G. Beastall2 &
M. Soukop'
'Departnment of Medical Oncology, Glasgoit' Royal Infirmlar
and 2Department ofBiochemistry, Glasgowt Roylal nfirmaryn,
Glasgow, UK.
The pathogenesis of cytotoxic induced emesis is still poorly
understood. Harris et al. (Lancet, i, 714, 1982) have
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of enzymes which degrade enkephalins, resulting in a rise in
their level in the blood and CSF, stimulating the vomiting
centre and inducing emesis. We have therefore measured the
levels of endorphine and (met) enkephalin in peripheral
blood in six patients receiving combination chemotherapy,
just prior to and for 12h after the i.v. administration of
cytotoxic agents. # endorphine and (met)enkephalin were
measured using a radio-immunoassay technique with
sensitivities of 5pmol 1 l and 2pmol 1 respectively.
In 2 patients who experienced no nausea or vomiting,
there was no rise in # endorphine or (met)enkephalin with a
main peak level of 3.85 pmol 1- 1 +0.97 (normal range 4-
6pmol - 1). The remaining 4 patients all experienced nausea
and vomiting after cytotoxic administration. In all patients,
the level of endorphine in the peripheral blood rose
- 30min prior to the onset of nausea and vomiting. The
mean peak level of endorphine reached was
22.2 pmol 1- 1 +4.68. The level of (met)enkephalin did not
significantly change in any of the patients, remaining within
the normal range (20-200pmol 1 1) before or after
chemotherapy.
These observations seem to suggest that changes in
endorphine levels may be important in the physiological
mechanisms of nausea and vomiting. The mechanism of
action remains unclear and requires further study. However,
this information may be used to provide a more rational
antiemetic approach in the future.
Anti-emetic activity of BRL43694, a novel 5HT3-receptor
antagonist
E.A. Boyle, W.D. Miner & G.J. Sanger
Beecham Pharmaceuticals, The Pinnacles, Harlow
CMJ9 5AD, UK.
We have suggested (Miner & Sanger, Br. J. Pharmac., 88,
497, 1986) that the anti-emetic activity of high dose meto-
clopramide (Mcp; Maxolon, Beecham) is due to 5HT3-
receptor antagonism. Using male ferrets, we now describe
the anti-emetic actions of a much more potent and selective
5HT3-receptor antagonist, BRL43694. Routinely,
compounds were given by venous cannulae and the ferrets
were observed for 120 min (post X-ray) or 240 min (post
cytotoxic drugs).
BRL43694 or Mcp were given by divided dose 30min
before and 45min after cis-platin (7 or 10mgkg-1). Mcp
dose-dependently reduced the number of emetic episodes
(89% reduction at 2x2.5mgkg-1). BRL43694 reduced
emesis by 93%, 96% and 100% at 2x0.005, 2x0.05 and
2 x 0.5mgkg- 1 respectively. BRL43694 2 x 0.5mgkg-
I also
protected against the emesis evoked by
doxorubicin/cyclophosphamide (6/80mgkg-1), being more
effective (96% inhibition) than 2 x 2.5mgkg- 1 Mcp (48%
inhibition). A single injection of BRL43694 0.5 mgkg-
I
10min before exposure to an X-ray source (-3Gymin-1;
Machlett model OEG-50; 50 kV/20 mA, tungsten anode)
abolished emesis. An oral dose of BRL43694 (0.5mgkg-1)
reduced radiation-evoked emesis by 94% when given 60min
before exposure. For all emetic stimuli tested, a single dose
of BRL43694 (0.5mgkg-' i.v.) arrested vomiting within 15
to 60 sec when given during an emetic episode.
BRL43694 is well tolerated in the ferret, does not cause
sedation and shows potent anti-emetic activity by either the
i.v. or oral routes.
The effect of metoclopramide on the bioavailability of TCNU
P.S. Warrington, J.S. Macpherson & J.F. Smyth
Medical Oncology Unit, Western General Hospital, Edinburgh
EH4 2XU, UK.
TCNU (T) is a new, orally administered nitrosourea which
causes dose-related nausea and vomiting. The anti-emetic
metoclopramide (M) alters the bioavailability of T. Nine
patients were entered into the study. Anti-emetics were not
prescribed with the first course of T but all patients received
M (30 mg i.v. bolus) 20min before the administration of
their second treatment course. Plasma samples analysed by
HPLC showed a significant increase in the Cpmax of T
when given with M and the Tmax was significantly reduced.
These results could have clinical significance if activity or
toxicity are related to peak concentration and highlight the
need for standardising anti-emetic treatment in multicentre
trials.
Cpmax ngml-I Tmax (min)
Patients T T+M T T+ M
1 957 1865 60 15
2 2913 2493 30 30
3 668 1389 60 45
4 861 1841 120 45
5 1339 1388 30 15
6 1092 1356 30 45
7 1202 2534 30 30
8 934 1219 60 30
9 890 1827.5 60 30
P<0.05 Wilcoxon signed rank test
The pharmacokinetics of morphine and morphine glucuronides
in normal volunteers after 4 routes of administration
R.J. Osborne, S.P. Joel & M.L. Slevin
ICRF Department ofMedical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
Morphine is the most important analgesic used to treat
cancer pain. The metabolite morphine-6-glucuronide (M6G)
is known to have pharmacologic activity and, in animals, its
potency is several times greater than that of morphine.
Investigation of the pharmacokinetics of this metabolite may
cast some light on the relative contribution of morphine and
M6G to the clinical effects of morphine treatment. The
pharmacokinetics of morphine and morphine glucuronides
(M6G, M3G), have been determined in 5 volunteers after
administration of morphine intravenously (i.v.), and as oral
(p.o.), buccal (B) and sublingual (SL) tablets. A specific
HPLC assay was used, with fluorescence and electrochemical
detection (J. Chromatogr. 375, 174, 1986). The table shows
mean AUC (ngml- . hmg- I dose, corrected to 70kg), mean
time to peak concentration (t.max) (h), and median
terminant elimination half life (t.0) (h).
Morphine M6G M3G
Route AUC t.max t.2 AUC t.max t.2 AUC t.max t.2
i.v. 8.5 - 1.6 17.7 0.8 2.7 99.3 0.2 4.8
p.o. 1.8 0.85 1.5 14.1 1.4 - 89.7 1.1 -
SL 1.9 1.5 1.9 15.3 2.2 - 89.8 2.1 -
B 1.8 2.0 2.4 12.7 2.9 - 61.3 2.9 -
M6G is more abundant than morphine and persists longer
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variability - range 1.3-17.8 h). If data from animal studies
for analgesic activity of M6G can be substantiated in man,
these results suggest that M6G is the major active
component of non-parental morphine (M6G:M AUC
ratio =7.6) and that it contributes substantially to the
duration of activity of both i.v. and non-parenteral
morphine.
An easy (ESI) approach to assessment and quality of life in
cancer patients
S. Bindemann' & M. Soukop2
'Phoenix Foundation, Ross Hall Hospital, Glasgow and
2Department ofMedical Oncology, Glasgow Royal Infirmary,
Glasgow, UK.
Anxiety and depression are 'markers' to psychological and
psychiatric morbidity, of universal acceptance and value.
Accurate assessment of these states should therefore possess
predictive value, so far as quality of life in cancer patients is
concerned. In order to achieve precise measurement in large
populations, a questionnaire, capable of providing an
unambiguous score indicating reactive (appropriate) anxious
or depressed state, through adjustment disorder, to evidence
of major psychopathology, would be required. Items
diagnostically associated with anxiety and/or depression, but
describing physical symptoms of advanced malignancy,
would be excluded. The Effects of Serious Illness (ESI)
(pronounced 'easy') Scale is a self-report questionnaire,
which incorporates subscales for the measurement of Anxiety
and Depression (Form A) and Physical Status (Form B).
Individual items (32 in all) are rated on 'frequency' and
(severity/intensity' criteria and the ESI Scale incorporates a
readily applied method for scoring and the assessment of
internal reliability and consistency. A readily applied scoring
stencil has also been developed. Early data shows a high
correlation (+0.8) when compared with scores obtained
from the same population via the Leeds Anxiety and
Depression Scales (LSA, LSD). Normative data relating to
'normal range', 'appropriate reactive state' and 'evidence of
pathology' will also be reported. The ESI Scales show
considerable promise as a quick and accurate screening
instrument for psychological morbidity in diverse patient
populations.
Reversal of cachexia induced by a transplantable colon tumour
in mice by flavone acetic acid (LM975)
M.C. Bibby & J.A. Double
Clinical Oncology Unit, University ofBradford, West
Yorkshire BD7 JDP, UK.
MAC 16 is one of a panel of tumours initially induced by
1,2-dimethyl hydrazine. Like the majority of the other
tumours in this series it is a slow growing adenocarcinoma,
but unlike the others it has large areas of necrosis and its
growth is accompanied by severe body wasting in the host.
Initial chemotherapy studies showed MAC 16 to be only
poorly responsive to standard agents. These observations
suggest MAC 16 may be the most clinically relevant of the
MAC series. LM 975 has been shown to be highly active in
established solid transplantable tumours (Bibby et al., Br. J.
Cancer, 55, 159, 1987). This study examines the chemo-
sensitivity of MAC 16 to a series of cytotoxic agents
including LM 975. Tumours are transplanted by
implantation of trocar fragments in the flank. Chemotherapy
commences when tumours can be reliably measured and
anti-tumour effects are assessed by serial twice weekly caliper
measurements. The tumour was unresponsive to cyclo-
phosphamide, 5-fluorouracil and ThioTEPA contrary to our
previous findings (Ali et al., Br. J. Cancer, 52, 452, 1985)
and also to chlorambucil, DTIC, methylCCNU and
mitozolomide. LM975 proved more toxic to mice bearing
the MAC 16 tumour than those bearing other MAC lines,
however significant anti-tumour activity was seen. Responses
were accompanied by reversal of the cachexia similar to that
seen following surgical excision. The alteration in chemo-
sensitivity to standard agents might be explained because
serial passage was biased by selection for the cachexia. The
resultant tumours are also more ischaemic and necrotic and
this may influence drug bioavailability. These results would
suggest that LM 975 has a novel mechanism of action which
is possibly dependent on specific biological properties of the
tumours.
Posters
Enhanced recognition of colorectal tumours using combinations
of monoclonal antibodies
L.G. Durrant', K.C. Ballantyne3, V. Byers2,
J.D. Hardcastle3 & R.W. Baldwin1
1Cancer Research Campaign Laboratories, University of
Nottingham, Nottingham, UK, 2XOMA Corporation,
Berkeley, CA, USA and 3Department ofSurgery, Queens
Medical Centre, Nottingham, UK.
Several monoclonal antibodies (Mabs) recognising tumour
associated antigens are currently being evaluated for therapy
of human cancer. Variations in antigen expression on
tumour cells could produce difficulties in recognition of cell
tumours. One approach to this problem is to use a
combination of Mabs which recognise several distinct surface
epitopes.
Immunophenotypes of 50 primary colorectal tumours have
been analysed to select an appropriate combination of Mabs.
The optimum combination of Mabs would consist of C14
recognising Y haptenic blood group, 791T/36 recognising
79lTp72 antigen, 365 recognising carcinoembryonic antigen
and B14/B8 recognising normal cross reacting antigen. This
combination would recognise all of the colorectal tumours,
60% of them binding in all 4, 18% any 3, 12% any 2 and
10% binding a single Mab.
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When cultured cells were stained with these Mabs the
intensity of binding and the number of cells recognised was
increased by using combinations of Mabs. When cells were
treated with ricin A toxin (RTA) conjugated to 3 different
antibodies, it was almost as cytotoxic as when it was
conjugated to the most effective single antibody.
Inter and intra tumour heterogeneity can be reduced by
using combinations of Mabs recognising distinct epitopes.
Red cell filterability in cancer patients
M.L. Slevin, S.P. Joel, A. Bramley, M. Schofield, D. Trew,
C. Lewis, W. Gregory & P.F.M. Wrigley
ICRF Department ofMedical Oncology, St Bartholomew's
and Homerton Hospitals, London, UK.
It has been suggested that red cell filterability (RCF) may be
reduced in cancer patients and this is related to stage of
disease; also that priming with chemotherapy prior to
treatment corrects RCF and that this improves treatment
results. In order to investigate this, RCF has been studied in
100 cancer patients at a diagnosis and 100 age/sex and time
matched controls (Study A). In a further study 15 small-cell
lung cancer (SCLC) patients receiving single agent etoposide
(total dose 500mgm 2) had RCF measured before, during
and after cycle 1 of chemotherapy (Study B). RCF
measurements were made using a filtration technique
employing a 1% suspension of washed red cells and a 3pim
polycarbonate membrane. Haematological and biochemical
profiles and clinical data were recorded. In Study A
Univariate analysis showed a significant difference
(P=0.023) in RCF between the patient (mean RCF=0.219)
and the control group (mean RCF=0.235). However, when
differences in other biochemical parameters, notably
albumin, were taken into account using multivariate analysis
there was no longer a significant difference in RCF. There
was no significant relationship between RCF and stage of
disease. In 45 patients on whom RCF measurements were
repeated after 3-6 months there was no relationship between
change in disease state and RCF. Variability in these repeat
samples was much larger in the patient group than in
controls. In the SCLC patients treated with etoposide (Study
B), post-treatment RCF was significantly higher than pre-
treatment values (P=0.0007) and showed an improvement in
12 of 15 patients (median increase 16.3%). In conclusion
RCF is not altered in cancer patients or by changing disease
state, but may be improved by chemotherapy.
A DNA cytophotometric study of neoplastic field change in the
human urinary bladder
A. O'Brien', A. Dorman2, M. Butler1 & J.M. Fitzpatrick'
'Department of Urological Research, Meath Hospital, Dublin
and 2Department ofPathology, St James's Hospital, Dublin,
Fire.
Hofstaedter et al. (Br. J. Urol., 56, 289, 1984) have shown
that the Diploid Deviation Quotient (DDQ) is a reliable
indicator of future behaviour of bladder tumours,
irrespective of grade or stage, in that the survival of patients
whose tumours had DDQ's< 1.2 did not differ from that of
controls, whilst a DDQ> 1.2 was associated with a poor
prognosis (P<0.05). The aim of this study was to apply
DNA cytophotometry to the assessment of neoplastic field
change in the bladder. Cold cup biopsies of endoscopically
normal mucosa were taken from 7 predetermined, disparate
sites in each of 10 bladders containing a tumour, as well as a
biopsy of the tumour itself. Similar biopsies from 10 benign
bladders acted as controls. Adjacent cuts from each specimen
were submitted for histopathology and cytophotometry using
a scanning microdensitometer.
Histological examination revealed that 4 (6%) of field
biopsies contained frank tumour, 6 (9%) carcinoma-in-situ
(CIS), 13 (19%) varying types of cystitis, and 44 (66%)
normal. Two of those with tumour, all of those with CIS
and 4 of those with cystitis had a DDQ>1.2. However, it
was surprising to find that 20 (45%) of the histologically
normal biopsies had a DDQ> 1.2 (P<0.01). Moreover, in 10
of these cases, the associated tumour had a DDQ < 1.2. This
study would indicate that this technique may be able to
identify histologically normal mucosa already committed to
neoplastic change, and that such mucosa may have even
greater eventual prognostic implications than the associated
overt tumour.
In vitro and in vivo ectopic production of immunoreactive
fihCG by neoplastic and normal bladder epithelium
R.K. Iles', R.T.D. Oliver', M. Kitau2 & T. Chard2
'Medical Oncology Unit, Department of Urology, The London
Hospital Medical College, London El and 2Department of
Reproductive Physiology, St Bartholomew's Hospital Medical
College, London EC], UK.
Beta chain human chorionic gonadotropin (,BhCG) was
demonstrated in the culture medium of 6 out of 8 neoplastic
and 4 out of 5 'normal' human bladder epithelial cell lines
by RIA Levels ranged between 34 and 2,376iu -1, while
controls ranged between 15 (detection limit) and 24iul-1. In
contrast, none of the 8 testicular germ cell tumour cell lines
secreted detectable levels of,BhCG.
Using a cDNA probe, it was shown that the ,BhCG gene
cluster was not amplified in any of these cell lines.
The production of this protein was suppressed significantly
by rIFN-y but not IFN-oa. The IFN-y suppression was
coincidental with induction of MHC class II antigens by
these cells.
Urine samples from clinically normal individuals and those
with active bladder cancer both demonstrated measurable
levels of,hCG, although the highest levels were observed
within the cancer group.
The experimental results indicate that immunoreactive
,BhCG can be produced by the urothelium, and this may
prove a useful marker of tumour development and
progression.
Correlations between the clinical, haematological and
immunological features of B-cell leukaemias
N.S.A. Stuart', P.R. Richardson2, I.C.M. MacLennan2 &
N.R. Ling2
'CRC Clinical Trials Unit and 2Department ofImmunology,
Universtity ofBirmingham, Birmingham, UK.
The surface antigen expression by neoplastic B-cells from
109 patients with B-cell leukaemia (98 chronic lymphocytic
leukaemia (CLL), 11 hairy cell leukaemia (HCL)) was
investigated using a panel of B-cell antibodies. Correlations
were sought between the surface phenotypes and the clinical,
haematological and immunological features of the patients'
disease.
1. Differences in antigenic expression between CLL and HCL
Several phenotypic differences were found between CLL and
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expression in HCL than CLL while CD22, HD55, 109-3C2,
KiB3 and to a lesser extent 2-7 showed more expression in
HCL than CLL.
2. Correlations betwveen expression of diflerent antigens
Some antigens were expressed on only a proportion of cases
of CLL. Correlations were sought between the expression of
these antigens to look for patterns of co-expression. Antigens
CD21, NUB-1, CDw4O, and CD39 were closely correlated
usually being expressed together as were CD21, CD9 and
CD23.
3. Correlationis betwt,een antigenic expression and clinical
fi'atures of CLL
Analysis of the phenotype of CLL cells in relation to clinical,
haematological and immunological features of patients'
disease did not identify any clear disease groups. However
younger patients had significantly less cells expressing mouse
red-cell receptors (P<0.001) and more cells expressing CD20
(P=0.03). Patients whose neoplastic B-cells expressed Ki-B3
had lymphadenopathy significantly more often (P=0.002)
than those whose neoplastic cells did not and also had more
advanced stage of disease (P=0.01). Serum IgG and IgM
were higher in patients with B-cell clones expressing SHCL-2
a difference not attributable to the presence of a paraprotein.
Patients whose malignant B-cells expressed both sIgM and
sIgD had significantly lower expression of M-RBC
(P=0.006), CD23 (P=0.0001) and NUB-I (P=0.03) than
those expressing either sIgM or sIgD alone. B-cell clones
expressing kappa light-chain had higher expression of CD20
(P=0.01) and CD21 (P=0.05). There were no correlations
with overall survival or treatment-free interval though
follow-up is at present relatively short.
Treatment of small cell lung cancer (SCLC) with late
intensification following a standard induction chemotherapy
regime
P.D.J. Hardman, J.A. Green, R.D. Errington &
H.M. Warenius
Department of Radiation Oncology, Clatterbridge Hospital,
Behington, Wirral, MerseYlside L63 4JY, UK.
Seventy-seven consecutive, previously untreated patients with
biopsy proven SCLC received initial treatment with CAV
chemotherapy (cyclophosphamide 1 gm-2, adriamycin
40 mg m-2, vincristine 1.4mgm -2 i.v. q. 21 days) to CR plus
2 cycles. The 43 men and 34 women had a median age of 62
years (range 33-71 years). Twenty-eight patients had
extensive disease and 49 patients had limited disease. Results
were as follows: 29 CR (39%), 27 PR (36%). 14 SD (19%) 4
PD and 3 NE. Thirty-seven patients went on to receive 2
cycles of IMVP-16 chemotherapy (ifosfamide 5gm2, mesna
7gm -2, methotrexate 30 mgm -2 on day I, VP16
lOOmgm-2 i.v. for 3 days i.v. q. 28 days). Five patients were
converted from PR to CR by IMVP-16, giving a total of 34
CR (44%) rate. The CAV induction schedule caused only 2
episodes of neutropenic fever. There were 3 deaths on
IMVP-16 and 5 further episodes of neutropenic fever,
(13.5%). Of this group, 20 have undergone interval
bronchoscopy of which 14 (70%) showed no evidence of
tumour. Thirteen out of the 34 patients in CR went on to
receive planned radiotherapy to the brain (30Gy) and to the
involved lung field (45 Gy) and a further 5 required local
radiotherapy on relapse. The median survival figures were:
overall 9 months, CR patients 11.5 months, LIM 12 months,
EXT 5 months. This sequential treatment regime is feasible
and gives results comparable to those in other large series.
There is no evidence to date that intensification with IMVP-
16 chemotherapy, or local radiotherapy are associated with a
prolongation in survival.
Carboplatin (Cp), VP16 (V) and ifosfamide (I) intensive
chemotherapy (CT) for small cell lung carcinoma (SCLC)
T.J. Perren, M.D. Vincent, M.E. Gore, J.R. Yarnold &
I.E. Smith
Lung Un7it, Royal Marsden Hospital, Sutton, SurreY, UK.
Cp+V has proved very active against SCLC (85% response)
but with short duration. A more intensive full dose 3-drug
combination of Cp 400mgm 2 i.v. day 1, V 10mgm 2 i.V.
days 1-3, and 1 5gm-2 day I (24h infusion) with mesna, q.
28 days x 6 courses has therefore been used in 31 fit (ECOG
performance status 0-2) previously untreated SCLC pts.
Limited disease (LD) patients also received hyperfractionated
thoracic radiotherapy concurrently with the first 2 CT
courses (15 Gy x 15 # x 5 days x 2 courses). Twenty-seven pts
(18 males) are evaluable (>2 courses CT), median age 60
(30-70) yrs. Response is as follows:
Overall
Patients CR PR response
LD 13 7 (54%) 5 12 (92%)
ED 14 4 (29%) 10 14 (100%)
Six ED and 2 LD patients (I CNS alone ) have relapsed;
median follow-up is <1 year. Main toxicity was myelo-
suppression: 15 (56%) patients required dose reduction, I
(4%) treatment delay, and 2 (7%) had treatment deaths.
Main toxicity details are as follows:
WHO Gracle
0 1-2 3-4
WBC suppression 1 0 26 (96%)
Platelet suppression 3 2 (7%) 22 (81%)
Infection 8 10 (370/o,) 9 (33%)
Nausea/vomiting 0 14 (50%) 13 (50%)
Alopecia 0 1 (4%) 26 (96%)
There was no significant neuro-, nephro- or other toxicity.
This intensive combination is feasible and highly active but
causes severe marrow suppression, and would only be of
clinical value if it can achieve good long term control.
Acute phase reaction in patients with small cell lung cancer
undergoing chemotherapy
R. Milroy, D. Shapiro, A. Shenkin & S.W. Banham
Departments ofRespiratory Medicine cnd Biochenmistry, Royval
InfirmarY, Glasgow G31 2ES, UK.
The level of acute phase reactant C-reactive protein (CRP) is
raised in inflammatory reactions and tissue destruction and
in malignant disease (Raynes & Cooper, J. Clin. Pathol., 36,
798, 1983). We have measured CRP levels in patients with
small cell lung cancer undergoing their first pulse of
induction chemotherapy to assess if there is evidence of an
acute phase response to chemotherapy and to relate this to
subsequent tumour regression. CRP levels were measured on
at least 3 consecutive days in .20 patients with small cell lung
cancer during their first pulse of chemotherapy. Restaging
after 4 cycles showed 7 patients had a complete, 4 a partial
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evaluable.) Mean baseline CRP level was elevated
(24.7mgl-') and a dramatic rise in CRP was seen in 14 of
20 patients with levels more than doubling some 24-48 h
after induction therapy commenced. Four of the 7 patients
who entered complete remission showed this type of acute
phase response (CRP peaks >40mgl- 1). Two of the
remaining 3 patients had low baseline CRP levels with no
rise during chemotherapy, possibly reflecting their
documented low tumour burden at outset. These data
indicate that there is a previously undescribed quantifiable
acute phase reaction following chemotherapy the significance
of which merits further investigation.
Neoadjuvant chemotherapy and radiotherapy in non-small cell
lung cancer (NSCLC)
S.W. Watkin, R.D. Errington, J.A. Green & H.M. Warenius
CRC Department of Radiation Oncology, Clatterbridge
Hospital, Wirral, Merseyside L63 4JY, UK.
This pilot study examines the feasibility of the sequential
combination of a 4 drug combination regime followed by
lung irradiation in NSCLC. Twenty-three patients (16 male,
7 female) with NSCLC have been entered into the study.
The mean age was 53.8 years (range 35-71 years) and
histology was squamous 12, adenocarcinoma 4, large cell 2,
undifferentiated 4, and alveolar cell carcinoma 1. Patients
were given adriamycin 40mgm 2, vindesine 3 mgm 2,
ifosfamide 5 gmm - 2 with mesna and cis-platin 60mgm -2, q.
28 diys for 3 cycles. Of 17 evaluable paticnts. thlei have
bcen 2 CR, 7 PR, 5 SD and 3 PD, giving an overall responsc
rate of 53% to chemotherapy. Seven have died and the
median survival is 6 months (1- to 18 months), with 2
patients alive at 15 and 18 months. Blood transfusion has
been required in 5 and there have been 3 episodes of
neutropenic fever and no treatment related deaths. Radio-
therapy to a total dose of 4,800cGy in 16 fractions has been
given to 15 patients and was not associated with untoward
side effects.
This study has demonstrated that this 4 drug intensive
chemotherapeutic regime produces favourable response rates
in NSCLC with acceptable toxicity. It remains to be shown
whether the combination of chemotherapy and radiotherapy
leads to increased survival in this disease.
Immunohistochemical phenotype related to prognosis in small
cell lung cancer (SCLC)
(neuron specific enolase (NSE)), and protein gene product
(PGP); epithelial antigens (HMFG2 and AuA1); cytokeratins
(5.2 and LP34) and natural killer cells (Leu 7).
Tumours were scored as either negative or positive, and
the percentage of positives in short (S) and long (L)
survivors were: NSE 100% (S), 100% (L); PGP 100% (S),
84.2% (L); HMFG2 92.8% (S), 73.6% (L); AuA, 85.7% (S),
63.1 % (L); 5.2 92.8% (S), 63.1 % (L); LP34 7.1 % (S), 0%
(L), and Leu7 30.7% (S), 50% (L). The results so far do not
suggest that the prognosis of SCLC can be related to
immunohistochemical phenotype using markers which
recognise epithelial and neuroendocrine antigens. The study
is being extended to include more specimens to determine if
the small difference in positivity with Leu 7 is genuine.
Measurements of in vitro drug sensitivity to human myeloma
and chronic lymphocytic leukaemia
A.G. Hall, A.M. Dickinson, E.A. Jacobs & S.J. Proctor
Department ofHaematologj, Royal Vietoria Infirmary,
Newcastle upon-Tyne NE] 4LP, UK.
Assessment of drug sensitivity to treatment is multiple
myeloma would be of great clinical benefit. We have been
attempting to measure drug sensitivity of myeloma plasma
cells to melphalan using 2 independent in vitro techniques.
One is a recently described cytotoxic assay (Bird et al.,
Hematol. Oncol., 3, 1, 1985) using supra-vital staining with
fast green and nigrosan and the other an in vitro colony
assay using 0.9% methylcellulose (Durie et al., Blood, 61, 5,
1983). Separation of plasma cells using Percoll Density
gradients (Atherton et al., 55, 271, 1985) has enabled us to
concentrate plasma cells from bone marrow aspirates
containing as few as 10% tumour cells. Preliminary results
using these in vitro methods have measured drug sensitivity
of plasma cells down to 0.1 ,pgml 1 melphalan.
Further studies involving in vitro drug sensitivity of
chronic lymphocytic lymphoma (CLL) to chlorambucil and
melphalan are in progress.
The relative value of bone marrow aspirate and trephine in
staging non-Hodgkin's lymphoma
R.S. Evely & B.W. Hancock
Department ofMedicine, Royal Hallamshire Hospital,
She/field, UK.
L. Morittul, M.N. Sheppard2, L.G. Bobrow2 &
R.L. Souhamil
'Department of Radiotherapy and Oncology and 2Department
of Pathology, University College Hospital, London WCJ 6A U,
UK.
It has been suggested that those forms of SCLC showing a
'variant' phenotype in culture may be associated with a more
malignant clinical course.
We have retrospectively examined initial fibre-optic
bronchoscopy specimens of 370 patients treated in a single
clinical trial of SCLC. The aim was to determine if there was
an immunohistochemically defined phenotype which identi-
fied short or long survivors. Twenty-six specimens from
short survivors (survival time <4 months) and 36 from long
survivors (survival time > 12 months) were examined. Of
these 12 and 17 were discarded from the short and long
groups respectively because of traction artefact or
insufficient material. Using the avidin-biotin and the PAP
(peroxidase-anti-peroxidase) methods, we have utilised a
panel of antibodies which detect neuroendocrine markers
A prospective study in 123 patients with non-Hodgkin's
lymphoma, compared the relative value of performing both
bone marrow aspirate and trephine in routine staging. The
original reports for both procedures were classified into one
of three categories:
+ =Unequivocal marrow involvement with lymphoma
-=No evidence for marrow involvement with lymphoma
+ =Suspicious of marrow involvement with lymphoma
The results are tabulated below:









Trephine biopsy was valuable in distinguishing reactive
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detect infiltration in 7% of cases with positive trephine
biopsies; however the converse was also true. Six of the 9
patients with positive aspirate/negative trephine died of
lymphoma within 18 months of presentation, the majority
with obvious evidence of marrow involvement. Aspiration
seems to be complementary to trephine biopsy in the staging
of patients with non-Hodgkin's lymphoma.
Appetite and tryptophan in cancer patients
M.L. Slevin', S.P. Joel', W. Gregory', H. Plant',
L. Stubbs', A. Johnston2, M. Smythe2, D. Perrett3 &
T. Silverstone4
Departments of 'Medical Oncology, 2Clinical Pharmacology,
4Psychiatric Medicine and 3Medical Professorial Unit, St
Bartholomew's and Homerton Hospitals, London, UK.
It has been suggested that an increase in brain serotonin
results in decreased appetite, a common problem in cancer
patients, and that circulating free tryptophan (TRY)
correlates well with brain serotonin levels. Brain TRY levels
are influenced by 3 factors; other neutral amino acids which
compete for blood-brain transport, circulating albumin to
which it is bound and free fatty acids (FFA) which also bind
to albumin (Cancer Treat. Rep. 65, 15, 1981). This
hypothesis has been investigated by measuring all these
factors in a group of 218 cancer patients and 100 controls.
Food intake and appetite were also assessed.
Cancer patients
Normal Poor
Results Controls food intake food intake
Albumin 42.6 38.0 34.3 (P<0.001)
FFA 0.4 0.36 0.4 (P=0.007)
Total TRY 59.5 51.7 44.9 (P<0.001)
Bound TRY 46.2 38.3 30.6 (P<0.001)
Free TRY 13.3 13.5 14.4 (NS)
% Free TRY 22.3 27.0 33.7 (P<0.001)
Cancer patients had significantly lower albumin and total
bound TRY levels compared to controls, while % free TRY
was significantly higher. However, FFA became more
importantly, free TRY levels were unchanged. These
differences became more pronounced in the patients with
poor appetite, though free TRY levels were unaltered. These
findings were not influenced by differences in weight loss
between the patients.
The effect of performance status on survival
L.A. Gumbrell, I.R. Judson, S.E. Ashley & A.H. Calvert
Drug Development Section, Institutefor Cancer Research,
Sutton, Surrey, UK.
The purpose of Phase I clinical trial is to evaluate a drug's
toxicity and determine a safe dose and schedule for its use in
Phase II studies. One of the usual entry criteria is a life
expectancy of at least 3 months. Histology, disease stage and
tumour bulk are all routinely used to help determine this,
but can be unreliable prognostic factors. Is performance
status a more reliable indicator? We studied 58 patients (pts)
with ovarian cancer who were entered into a Phase I study,
age range 30-73 (mean 55). We investigated the effects of
age, performance status (PS), tumour volume, response to
previous chemotherapy, stage at relapse, pre-treatment
alkaline phosphatase, serum albumin, creatinine and FBC on
survival. The effect of WHO PS was marked:
Median survival





Two other variables had an independent effect on survival,
which was adversely influenced by Hb < 1 g dl- I or serum
albumin <30g l-1. Further analysis is required to define the
effect of previous cis-platinum treatment on anaemia in these
pts. Median survival in relation to albumin was 165d:
>35gl-1; 152d: 30-35g1-1; 50d: <30gl-1. From these
results we conclude that PS is a powerful prognostic
indicator. In this group of refractory ovarian cancer pts poor
survival was also predicted by a low albumin (<30g1-1).
These results strongly suggest that pts whose WHO PS is 3
or 4 should be excluded from Phase I clinical trials.
Computer-matched bone scanning; increased sensitivity shown
by clinical follow-up
D. Parker' & G. Hart2
IOncology Unit, Bradford Royal Infirmary, Duckworth Lane,
Bradford BD9 6RJ and 2Department ofNuclear Medicine,
Bradford Royal Infirmary, Duckworth Lane, Bradford
BD9 6RJ, UK.
Bone scan data on 72 consecutive scans has been analysed
by a series of computer programs to increase the sensitivity
of the technique.
An IGE 400A/T gamma camera was interfaced to a
Nodecrest data processor and scintiscans were acquired after
i.v. injection of 99mTc-MDP. A profile was selected down
the whole length of the spine and this was truncated to avoid
bladder uptake. The profile was then interpolated to a
standard length of 200 points to remove effects due to
different patient height; it was then normalised to a standard
count level. The profile was examined for statistically
significant deviation from a standard curve, obtained from
patients referred with benign conditions outside the spine.
Clinical and biochemical data were available on 68 of the
72 patients. Serum alkaline phosphatase was significantly
correlated with total abnormal counts and the scaled total
number of counts recorded. Forty-five of 68 (66%) of the
computer-matched scans (CMS) showed abnormal peaks in
the spine, compared with 18 of 68 (26%) of the visually
assessed scans. There were a further 13 visually assessed
scans which showed lesions outside the spine and which were
positive by CMS. Six patients with positive CMS had
equivocal visual scans and 8 with positive CMS had negative
visual scans.
The clinical state of the patients was reassessed at 14
months after the scan. Of the 6 patients with equivocal
visual scans and positive CMS, 5 had died of metastatic
disease and 1 was alive but with metastases. In the 8 patients
with negative visual scan and positive CMS, 5 have
developed metastatic disease and one of these has died. All 5
patients in these 2 groups who had positive CMS and
elevated alkaline phosphatase have died of metastatic
disease. Computer analysis appears to substantially increase
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Prospective validation of a simple formula for determining
carboplatin dosage
D.R. Newell, A.H. Calvert, S. O'Reilly, M. Burnell,
L.A. Gumbrell, F.E. Boxall, M.E. Gore & E. Wiltshaw
Drug Development Section and Section ofMedicine, Institute
for Cancer Research and Royal Marsden Hospital, London
and Sutton, UK.
Carboplatin has become established as a non-toxic platinum
complex with activity against a variety of human cancers.
Pharmacokinetic studies have shown that carboplatin is
eliminated primarily by renal excretion via glomerular
filtration (Harland et al., Cancer Res., 44, 1693, 1984). An
equation has been derived for calculating the dose required
to achieve a given area under the plasma carboplatin
concentration vs. time curve (AUC) taking into account
pretreatment glomerular filtration rate (GFR) (Calvert et al.,
Cancer Treat. Rev. 12 (supp. A), 51, 1985). Dose
(mg)=AUC (mgmlmin-1) x [1.2 x GFR (mlmin- )+201.
This equation has been used to determine the dose of
carboplatin required to treat 26 patients (35 courses) GFR
32-135ml min- 1. Free carboplatin plasma levels were
determined by atomic absorption spectrophotometry
following ultrafiltration (MW<50,000). Over the AUC range
3-7mgmlmin-1 (dose 200-1,000mg carboplatin), the ratio
of the predicted to the observed AUC was constant at 0.89
(95% limits 0.85-0.93). The correlation between plasma free
carboplatin clearance and GFR was linear (r=0.89) with a
slope of 0.94 (95% limits 0.76-1.11) in this patient
population. Non-renal clearance was 27mlmin- (95%
limits 13-41) and may be correlated with surface area. On
the basis of these data we propose, therefore, a modified
dose prediction equation for adults: Dose (mg) =AUC
(mgml- I min-1) x [GFR (mlmin-1)+25]. After 14 courses
of carboplatin given to previously treated patients, thrombo-
cytopenia (% pretreatment on days 14-23) correlated
linearly (r=0.85) with AUC, an AUC of 5mgml-1min-i
producing a drop of -50%. Using the modified equation
the carboplatin AUC required for optimal activity, with
manageable toxicity, can now be determined.
Glycoprotein synthesis in normal and malignant cervical tissue
M.E.R. O'Brien', M.E. Cowan2, B.E. Souberbielle3,
D. Luesley4, J.J. Mould5, A. Buchan2, G.R.P. Blackledgel &
G.R.B. Skinner2
'CRC Clinical Trials Unit, Queen Elizabeth Hospital,
2Department ofMedical Microbiology, Medical School, 3Selly
Oak Hospital, 4Department ofObstetrics and Gynaecology,
Dudley Road Hospital and 5Department ofRadiotherapy,
Queen Elizabeth Hospital, Birmingham, UK.
Glycosylated proteins have important roles in both cancer
and normal tissue e.g. cell surface membrane hormone
receptors, immunoglobulins and HLA antigens.
To study these glycoproteins in cervical cancer and normal
cervical tissue we have used an organ culture system adding
radioactive labelled sugars (14C and 3H fucose, mannose,
and glucosamine) and protein precursor (35S methionine).
The labelled glycoproteins are then separated by SDS-page
electrophoresis and autoradiographs analysed.
The incorporation of the sugar precursors appears not to
be directly dependent or related to the degree of protein
synthesis. To date 14 squamous cell carcinomas and 8
normals have been cultured with results available for 12
carcinomas and 8 normals. There is a large degree of
correlation between the normals and the abnormals.
Differences in favour of carcinoma appeared in the following
molecular weight clusters: 143-147kd (5/10 ca, 0/8 normals),
76-80kd (11/12 ca, 1/8 normals), 44-47kd (10/12 ca, 0/6
normals), 34kd (7/8 ca, 0/7 normals). Some of these
correlate with bands already described in different
carcinomas.
Organ culture is a useful technique for studying synthesis
in vitro in cervical cancer. We have highlighted an area of
interest (mol wt 76-80kd) for antibody formation.
Renal function following cis-platin (CDDP) and carboplatin
(JM8) chemotherapy
M. Teeling, R. O'Regan & D.N. Carney
Medical Oncology Unit, Mater Hospital, Dublin and
Department of Pharmacology, UCD, Dublin, Eire.
Acute evidence of renal tubular damage (RTD) as shown by
a significant rise in urinary BNAG is frequently observed in
patients receiving CDDP of JM8. However, the relationship
between acute changes in BNAG excretion- seen with each
administration of CDDP and JM8 and long-term RTD
remains uncertain. We have calculated long-term renal
function in patients who have completed chemotherapy with
CDDP (n=8) or JM8 (n=4) and who were at least 3
months (range 3-18 months) from end of therapy. At the
time of study, CDDP was administered with prehydration
and forced diuresis while JM8 was administered as a bolus
infusion over 30min. Renal function was assessed using
plasma creatinine and urea, Cr* EDTA clearance,
proteinuria, glycosuria, enzymuria (BNAG) and urinary
concentration and acidification. Plasma magnesium (Mg)
and urinary Mg excretion were also studied. The mean total
dose of CDDP administered was 856mg (range 540-
1,505mg) and JM8 2,758mg (range 2,725-2,850mg). Plasma
creatinine and urea levels were within the normal range for
all 12 patients studied. Only 1/8 patients who received
CDDP showed evidence of RTD (poor concentration and
acidification with urinary Mg wasting and hypo-
magnesaemia). None of the JM8 patients showed RTD.
Among 8 patients, followed prospectively from the time of
diagnosis, and who had shown a 2-20 fold rise in urinary
BNAG excretion with each cycle of chemotherapy, no
evidence of permanent RTD as assessed was observed at the
time of study. These results suggest (1) long-term RTD in
patients receiving either CDDP or JM8 is minimal as
currently administered (2) a poor correlation exists between
acute elevations of urinary BNAG with therapy and long-
term RTD suggesting that the value of BNAG, as a
predictor of long-term RTD in patients receiving CDDP or
JM8 is of questionable value.
CA 125 and survival in ovarian cancer
D. Parker, K. Patel, J. Alred, P. Harnden-Mayor &
B. Naylor
Oncology Unit and Department ofPathology, Bradford Royal
Infirmary, Duckworth Lane, Bradford BD9 6RJ, UK.
CA 125 is an epithelial membrane antigen which is of value
in monitoring patients with ovarian cancer. We have been
able to show that the initial level of CA 125 is also correlated
with survival in ovarian cancer.
CA 125 was assayed in 42 patients with epithelial ovarian
cancer using the Centocor 125 kit (CIS UK Ltd). The
patients presented after surgical diagnosis and/or debulking.
Using an arbitrary level of 250Uml-1, it was found that 13
patients had more than this level on presentation and 29
patients showed lower values. Median follow-up was 10
months. Median survival for patients with CA 125 greater
than 250 Uml - was 310 days, but for values less than
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250 Uml-1, the projected probability of survival is 0.91.
Logrank analysis shows a significant difference between the
survival of these 2 groups (x2 =7.79, 1 df, P= 0.003).
These results add to the evidence validating CA 125 as a
marker for common epithelial cancer of the ovary. It may be
possible to use the presentation CA 125 level with clinical
and other biochemical measurements to stratify patients for
treatment.
Familial teratoma: Case report and review
T. Young1, N. Affarra2, G. Forrest' & M. Soukop'
1Department ofMedical Oncology, Glasgow Royal Infirmary
and 2Department ofMedical Genetics, Royal Hospitalfor
Sick Children, Glasgow, UK.
The familial occurrence of certain cancers including family
cancer syndromes are well documented. Reports of familial
testicular tumours are relatively rare, there being only 44
case reports occurring in twin and non-twin brothers.
However, few have had the same histology. We here report
the first description of three non-twin brothers affected by
testicular tumours of similar histology. The brothers, PB, TB
and AB presented in 1971, 1974 and 1986, respectively. All
had been previously healthy with normal testicular
development. Review of histology showed all three to have
malignant teratoma of intermediate grade. Previous workers
have shown some of these tumours to have chromosomal
abnormalities. However, due to fixation of tissue at surgery
this could not be studied in our patients. However,
chromosomal analysis using ras gene probe in peripheral
leucocytes revealed no chromosomal abnormality and all
patients had normal karyotype. The absence of a
chromosomal abnormality in peripheral leucocytes may be
expected but if present would be a useful marker. We
suggest that where possible fresh tumour tissue should be
examined in all such familial cases for gene probing to
attempt to improve our understanding of tumour
development.
Peritoneal lavage fluid CA 125: A means of increasing
sensitivity for this tumour marker in epithelial ovarian cancer
(EOC)
C.W.E. Redman, F.G. Lawton, K.K. Chan & G. Blackledge
West Midlands CRC Clinical Trials Unit, Queen Elizabeth
Hospital, Birmingham, UK.
Non-nvasive assessment of small volume residual disease in
epithelial ovarian cancer remains difficult despite the recent
advent of the serological tumour marker CA 125. Serum
CA 125 levels correlate well with disease response but there is
a false negative rate of 10-20% in bulky disease, and 40-
50% in patients in apparent complete remission (Berek et al.,
Obstet. Gynecol., 67, 685, 1986). Ovarian cancer remains
intraperitoneal throughout most of its natural history, and
therefore peritoneal lavage fluid (PLF) CA 125 may be a
better indicator of minimal disease.
We are studying CA 125 levels in PLF and correlating
these with serum levels. Ten patients with clinically evaluable
EOC, 29 women undergoing surgery for gynaecological
condition other than EOC (ovarian cyst 4; fibroids 2;
endometriosis 2; dysfunctional uterine bleeding 9; cervical
squamous cell carcinoma 5; misc. 4) and in 3 patients
receiving chronic peritoneal ambulatory dialysis (CAPD)
were studied in this way. Peritoneal lavage with 11 normal
saline was performed via a percutaneous cannula in 8
patients (ovarian cancer 5; CAPD 3), and during operation
in the remainder. No problems were experienced during this
procedure, which was carried out on an outpatient basis for
those patients with a percutaneous catheter. CA 125 levels
were measured using the Centacor CA 125Tm RIA test.
Serum CA 125 levels for the cancer group were all
elevated, 77-475 U ml (mean 195). PLF levels correlated
with these, 84-499 U ml '(mean 243). Both serum and PLF
levels were significantly higher in the cancer group than the
controls (P=0.01). These results indicate that PLF can be
safely obtained and that the CA 125 levels correlate with
those in serum. Further studies are underway in patients
with clinically inevaluable disease to determine whether PLF
CA 125 levels may be a more sensitive indicator of disease
residuum.
A comparison of serum tumour markers in patients with
ovarian carcinoma
J.N. Gennings', A.E. Nelstrop', D.S. Northcott',
G.J.S. Rustin', H.J. Lambert2 & K.D. Bagshawel
(for the N.W. Thames Ovary Group)
'Department ofMedical Oncology, Charing Cross Hospital,
London W6 and 2Department ofRadiotherapy, Hammersmith
Hospital, London W12, UK.
Serum samples have been collected from patients with
ovarian carcinoma, and records kept of stage of disease,
treatment and clinical status.
Tumour marker CA 125 was measured in serum by ELISA
(Abbott Labs kit).
Assays have been developed in the Department of Medical
Oncology, Charing Cross Hospital using a 'family' of
monoclonal antibodies which may bind to related antigenic
epitopes. The following antibodies were investigated:
HMFG-1, HMFG-2, M8, NCRC-Il and 115D8.
These assays were used to establish marker levels in serum
from a normal population and in the ovarian cancer
patients.
In an initial pilot study, serum was assayed from 20
patients with active disease. The percentage of patients with
elevated levels of the markers was as follows: CA 125 95%;
HMFG-1 5%; HMFG-2 60%; M8 60%; NCRC-11 55%;
115D8 55%.
In 100% (20/20) of patients at least one of the markers
was elevated, and excluding CA 125 80% (16/20) expressed
an abnormally high level of at least one marker.
Comparison of the different assays in terms of the relative
numbers of patients who express these markers, and in the
correlation of marker levels with the patients' clinical status
has been undertaken.
Expression of histocompatibility antigens on human
ovarian tumour cells
RCF Leonard & F.G. Hay
University Department ofClinical Oncology, Western General
Hospital, Edinburgh EH4 2XU, UK.
Our previous experience of phenotyping the tumour cells in
human ovarian carcinoma ascites indicated frequent
anomalous expression of MHC class II antigen as defined by
the pan reactive anti MHC class II antibody CR3.43. We
have extended our original observations and have compared
the pattern of expression in ascites from 18 individuals using
a panel of anti MHC class II reagents. Our current
interpretation of the data is that anomalous class II
expression is especially strong in the less well differentiated
adenocarcinomas but relatively less so in better differentiated
serous adenocarcinomas. Loss of MHC class I antigens,
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HLA-A-B-C heavy chain anti class I antibody 92.1, is a
frequent finding but does not correlate positively or
negatively with anomalous expression of class II antigen.
Using cell lines derived from such tumours we are examining
in detail the extent of this anomalous expression and
attempting to determine possible preferential expression of
the sub-locus antigens DP, DR and DQ.
Characterisation and properties of 9 human ovarian
adenocarcinoma cell lines
S.S. Lawrie, S.P. Langdon, I.P. Hayward, A. McDonald,
M. Hawkes & J.F. Smyth
Inmperial Cancer Research Fund Medical Oncology, Unit,
Wester-n General Hospital, Edinburgh, UK.
Several series of cell lines have been derived from patients
with ovarian cancer. Nine cell lines have been established; 8
from malignant effusions; I from a solid metastasis. Tumour
cells were washed (RBCs removed over Ficoll-hypaque),
plated at I05ml- I in RPMI 1640+FCS with filtered non-
autologous human ascitic fluid, refed weekly and subcultured
4 days to 6 months later.
Six lines were derived from poorly differentiated adeno-
carcinomas (PD): 3 lines (PEOI, PEO4, PEO6) from 1
patient, 2 lines from a second (PEAl, PEA2) and PE016
from a third. Three lines (PEO14, T014, PE023) were
derived from a well differentiated serous adenocarcinoma
(WD). PEAl, PEO14 and T014 were obtained prior to
treatment; PEOU, PEO4, PE06, PEA2, and PE023 after
chemotherapy and PEO16 after radiotherapy.
Each set of samples from individual patients produced
morphologically distinct monolayer cultures. PEOI, PEO4,
PEO6 grew as uniform polygonal cells while PEA], PEA2
grew in elongated swirls. PEO14, T014, PE023 formed foci
with small dense cells in the centre and large vacuolated cells
at the edges. PEO16 cells were stellate. Doubling times
varied between 36 and 120 h. CFEs on plastic were greater
for the PD lines (CFE= 1-2%) (except PEO16) than for the
WD lines (CFE<0.04%). Equal or higher coefficients were
observed in agar.
Histochemical staining revealed further differences. The
WD cell lines contained >90% cells positive for alkaline
phosphatase while the PD lines contained <10% cells
positive (except PEO16).
We are using these models of human ovarian carcinoma to
study chemosensitivity, mechanisms of drug resistance and
cell differentiation in this disease.
Oestrogen-receptor-related protein (P29), CEA, EMA, and
DD9-E7 in fine needle breast aspirates
E. Heyderman1, B.M.E. Brown', S.E. Larkin', S.R. Ebbs2
& T. Bates3
Depar tment of Histopathology, UMDS, St Thomas's
Hospital, SEI 7EH and Departments of Surgers l, 2King 1s
College Hospital SE5 9NU and 3 William Harvey Hospital,
Ashford TN24 0L2, UK.
The immunocytochemical localisation of oestrogen-receptor-
related proteins and of other epithelial markers in fine needle
aspirates of breast tumours is of potential value in the
selection of treatment and the prediction of outcome. A
prospective study of material from women with lesions
suspicious of breast cancer has been undertaken. An indirect
immunoperoxidase method and monoclonal antibodies
directed against the oestrogen receptor related protein (P29)
(antibody D5), carcinoembryonic antigen (CEA), epithelial
membrane antigen (EMA), cytokeratin (CAM 5.2), and
DD9-E7 a novel epithelial, myeloid and macrophage
marker were used. While the other antigens survive a
variety of fixatives, ethanol or methacarn fixation are
required to demonstrate P29. Initially 52 sets of smears were
made, fixed for 5min in absolute ethanol, and allowed to
dry before being sent by post for immunostaining. This
technique was inappropriate in a busy outpatient clinic. The
number of slides from a single case were sometimes too few,
and the number of tumour cells varied widely. Fixation of
the aspirate in methacarn-filled 1.5 ml microfuge tubes,
double embedding in 5% agar and paraffin wax, and cutting
of at least 10 sequential sections from each pellet was
therefore substituted. Ninety-two cases in all were studied.
Of the 52 smears 6 were P29 +ve, 4 were CEA +ve. 16
were EMA +ve and 22 were CAM 5.2 +ve (DD9 was not
used on smears). The morphology of the H&E sections of
the pellets was easy to interpret, as was the immunostaining.
Of the 40 pellets, 2 were unsuitable, 15 were P29 +ve, 14
were CEA +ve, 37 were EMA +ve, 31 were CAM 5.2 +ve
and 16 were DD9 +ve. The immunostaining results of the
pellets showed encouraging prediction of response to
endocrine therapy.
Expression of differentiation antigens by human mammary
tumours indicates endocrine responsiveness
A.D. Baildam, A. Howell, D.M. Barnes, L. Turnbull &
R.A. Sellwood
CRC Department of Medical Oncologyv and Department of
Clinical Research, Christie Hospital and Holt Radium
Institute, Manchester M20 9BX, UK.
The monoclonal antibodies HMFGI and HMFG2, raised
against milk fat globule membranes, recognise carbohydrate
epitopes on mucin line molecules in normal and malignant
mammary epithelial cells. Inasmuch as the epitopes
recognised by HMFGI and HMFG2 are most highly
expressed during lactation, they may be regarded as
differentiation antigens. In this study we tested the
hypothesis that endocrine response of human mammary
tumours is related to tumour differentiation as determined
by histological grade and HMFG antigen expression.
Formalin-fixed paraffin embedded sections of the tumours
from 168 patients with advanced, evaluable cancer of the
breast were stained by the immunoperoxidase method using
both antibodies. The proportion of cells which stained was
estimated from counts of 400 or more and was reproducible
to within 10%. In 56 tumours the percentage of cells stained
was counted on 2 occasions: agreement to within 10% was
seen in 45 of 56 (86%). There was a highly significant
association between antigen expression, oestrogen (ER) and
progesterone (PR) receptors and histological grade (HMFGI
vs. ER P=0.001, vs. PR P=0.001 grade P=0.009. HMFG2
v's. ER P=0.001, vs. PR P=0.001 and grade P=0.001).
Response (R) to endocrine therapy was related to the
number of cells stained (HFMG1 < 10% cells staining 16 of
61 (26%) responded, > 10% 70 of 107 (65%) responded.
HMFG2< 10% cells staining 10 of 47 (21%) responded,
> 10% 74 of 19 (62%) responded. Median survival was 24
months greater when > 10% cells stained. A multivariate
analysis of 42 possible prognostic factors for survival
indicated that PR was the most important factor
(P=0.00001); when PR was omitted the percentage of cells
stained with HMFGI was the most important. We conclude
that tumours that express these antigens are responsive to
endocrine therapy and associated with a good prognosis.
Their estimation gives similar information to steroid
receptors with the advantage that fixed archival material
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The pharmacokinetics of medroxyprogesterone acetate 1 g
daily following a loading dose of 4 g in 24 hours
P.A. Canney', S. Virdee2, T.J. Priestman', M. Dowsett2 &
T.N. Latiefl
'Department ofRadiotherapy, Queen Elizabeth Hospital,
Birmingham and 2Department ofEndocrinology, Chelsea
Hospitalfor Women, London, UK.
The average time to response of patients with advanced
carcinoma of the breast treated with high-dose medroxy-
progesterone acetate (MPA), 1 g daily in divided doses, is 9
weeks (Canney et al., Anticancer Res., 6(A), 391, 1986).
Pharmacokinetic data suggest that at this dosage level it can
take 4 to 8 weeks to achieve plateau serum levels in the
range of 100ngml-1 or higher. To evaluate the feasibility of
reaching therapeutic levels sooner, and so possibly effecting
a clinical response within a shorter period, we have
performed a pharmacokinetic study of MPA, g 6-hourly
for 4 doses followed by 1 g daily in divided doses thereafter.
Five patients have been studied to date. No acute toxicity
was seen. Considerable inter-patient variability in serum
levels of MPA occurred, with the peak serum level, after the
first dose, ranging from lOngml- 1 to 352 ngml- 1 between
individual patients. The times to achieve steady state serum
levels of lOOngml-1, or higher, were 42h, 120h and 10
days. In the remaining patient the serum level never exceeded
80 ngml 1 but plateaued at this level after 6 days.
Immunohistochemical staining for OER, epidermal growth
factors ER-D5, and P24 oestrogen regulated protein in breast
cancer
C. Wright', G. Horne', B. Angus', R. Sainsbury2,
G.K. Needham2, S. Nicholson2, A.L. Harris3 &
C.H.W. Horne'
'Department ofPathology, 2Department of Clinical Surgery
and 3Cancer Research Unit, University ofNewcastle-upon-
Tyne, Newcastle-upon-Tyne, UK.
Proteins regulated by or related to the oestrogen receptor
may prove to be more reliable indicators of prognosis and
hormone sensitivity than the receptor itself. An inverse
relationship between both tumour ER status and low tumour
histological grade, and epidermal growth factor receptor
content has been recently demonstrated. In a study of 60
breast cancers immunohistochemical staining was carried out
by an indirect immunoperoxidase technique on acetone fixed
freeze dried frozen sections using monoclonal antibodies
against oestrogen receptor (ER) (ERICA - King & Green),
epidermal growth factor receptor (EGFR1 - Waterfield),
ER-D5 oestrogen receptor related protein (King), and P24
oestrogen regulated protein (Adams & McGuire). In addition
tumour histological grade was determined, and radioligand
binding assays for ER and EGFR carried out. Immunohisto-
chemical staining grade was determined on a 5-point scale
from zero by 2 independent observers, and scores 1 or less
regarded as 'negative'. There was good correlation between
staining for both ER and RI, and the corresponding
biochemical assays thus providing validation of these
antibodies as determinants of receptor status. Relating ER
staining to EGFR status, very few ER positive cases were
EGFR positive, although the relationship falls short of
significance P<0.1. Seventy-one per cent and 43% of
tumours stained for ERD5 and P24 respectively but no
relationship was observed between staining for these and
other parameters examined. The significance of staining
using these antibodies must therefore await determination of
clinical outcome for these patients. Tumours of high
histological grade tended to be ER negative by immunocyto-
chemistry (P<0.05) but this relationship was not confirmed
by the biochemical assay.
Epidermal growth factor receptor quantitative assays: Cut-off
points of clinical relevance
S. Nicholson, J.R.C. Sainsbury, J.R. Farndon,
G.K. Needham & A.L. Harris
Departments ofSurgery and Cancer Research, University of
Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK.
Since 1983 epidermal growth factor receptor (EGFr) assays
have been performed on over 200 primary and metastatic
human breast tumours by a combination of two point assays
and Scatchard plots. Multipoint Scatchard analyses have
revealed 2 binding sites. The high affinity site, thought to be
of clinical relevance, was shown to have an affinity constant
of around 1-2nM (Sainsbury et al., Lancet, i, 364, 1985). In
an attempt to identify tumours with high affinity binding a
concentrati,on of 0.6nM labelled EGF was used in 2 point
assays. This is on the linear part of the binding curve. A cut-
off point of 10 fmolmg membrane protein was chosen, as
for oestrogen receptor. Follow-up data on over 140 patients
has shown a strong inverse relationship to oestrogen receptor
status and a positive correlation between EGFr, early
recurrence and death. Recent work has shown that
saturation of the high affinity site occurs in the majority of
cases at a concentration of I nM labelled EGF (kd 0.3-
0.6nM). A 2 point saturation assay is now used with I nM
labelled EGF (Sp. Act. -80-130 pCipg-1), 100 ug
membrane protein and 100nm unlabelled EGF for
calculation of non-specific binding, made up to a volume of
400,l with buffer. At a cut-off of 10 fmolmg this assay is
slightly more sensitive than before.
EGF receptor status of histological sub types of breast cancer
J.R.C. Sainsbury, G.K. Needham, S.R. Nicholson,
P. Chambers, J.R. Farndon & A.L. Harris
Departments ofSurgery & Clinical Oncology, University of
Newcastle-upon-Tyne, Newcastle-upon-Tyne, UK.
There is an inverse correlation between epidermal growth
factor (EGF) receptor status and oestrogen receptor (ER) on
human breast cancer specimens and patients with EGF
receptor +ve tumours have a poorer prognosis (Sainsbury et
al., J. Clin. Path., 38, 1225, 1985). Some histological
subtypes of breast cancer have a better prognosis. An
analysis of 191 breast cancer samples (assayed by a
radioligand binding assay - Sainsbury et al., Lancet, i, 364,
1985) has been made and the EGF receptor status correlated
with histological findings.
One hundred and seventy-two invasive ductal tumours
were assayed of which 62 (36%) were EGF receptor positive.
The previously reported negative association with ER status
was again found (8 tumours double +ve, 35 tumours double
-ve, 57 ER +ve and EGFr -ve and 54 tumours EGFr
+ve and ER -ve: Z2 =46.9, P<0.000001).
There were 10 lobular carcinomas (5%) of which 3 were
EGFr +ve. There was no clear cut relationship between
EGF and ER status for this small group of tumours. The
majority of the remaining 9 tumours were EGFr -vye (EGFr
shown first). Clear cell carcinoma -/+, 2 mucinous
carcinomas -/+ and 1 -/-, 1 carcinoid -/+, 1
fibrosarcoma -/-, 1 tubular -/+ and 2 cystosarcoma
phylloides of which 1 was -/- and I +/-. Thus only one
of the rarer tumours, with a better prognosis, was EGF
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support the hypothesis that EGF positivity is related to poor
prognosis.
Increased alkylating activity in patients with bronchogenic
carcinoma treated with a fractionated dose of ifosfamide
T. Cerny', J. Margison2, M. Lind', P.M. Wilkinson2 &
N. Thatcher'
'Department of Medical Oncology and 2Clinical
Pharmacology, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX, UK.
Ifosfamide (Ifos) is a prodrug which requires hepatic
activation. In 10 patients with bronchogenic carcinomas
alkylating activity in serial serum samples taken after a
fractionated daily oral or i.v. dose was assessed using a
modified nitrobenzylpyridine spectrophotometric method.
Serum Ifos levels were measured by an HPLC method
(Margison et al., Biomed. Chrom., 1, 3, 1986). We have
previously shown that the bioavailability of oral Ifos is
100%.
The serum alkylating activity (mean area under the curve)
was as follows:
Area under the
curve /gl- ' h-
Patients Daily dose Max
(n) Ifos Day I Day 2 Day 3 increase
4 2g i.v. 105 140 99 33% day 2
6 2g oral 131.1 264 239 101% day 2
These findings suggest that a fractionated dose of oral Ifos
may result in maximal serum alkylating activity, probably
due to induction of metabolism and this should be evaluated
further. Marked inter-individual variability, however, has
been found.
Non-invasive pharmacokinetics of misonidazole and
chlorambucil analogues by 19F nuclear magnetic resonance
spectroscopy
P. Workman', R.J. Maxwell2 & J.R. Griffiths2
'MRC Clinical Oncology and Radiotherapeutics Unit,
Cambridge and 2CRC Biomedical Magnetic Resonance
Research Group, Department of Biochemistry, St George's
Hospital Medical School, London, UK.
Nuclear magnetic resonance (NMR) offers exciting potential
for the non-invasive investigation of antitumour agent
pharmacokinetics in animals and man. The most favourable
atomic nucleus is 19F which gives an intense signal with low
endogenous background. Here we report the feasibility of
studying the biodistribution in mice of (1) /3,/3-difluoro-
chlorambucil, fl-F2CHL, a fluorinated analogue of the
alkylating agent chlorambucil, and (2) Ro 07-0741, 1-(2-
nitroimidazol-I-yl)-3-fluoropropan-2-ol, a fluorinated
analogue of the hypoxic cell sensitiser misonidazole. Drugs
were administered i.p. to C3H/He male mice bearing the
KHT fibrosarcoma im in the leg, fl-F2CHL at 45mgkg-1
and Ro 07-0741 at 473mgkg-1. Mice were anaesthetised
with urethane or sodium pentobarbitone. A 15mm diameter
radiofrequency surface coil was placed externally over the
liver, tumour or skull. 19F spectra were recorded with a 1.9
Tesla Oxford Research Systems TMR-32 spectrometer using
a frequency of 75.5 MHz, a 1 sec pulse repetition time, and a
spectral width of 4kHz. Spectra were obtained by averaging
480-960 pulses (8-16min). Relative quantitation was by peak
area. f3-F2CHL was identified reproducibly in liver for up to
3h post-injection. It was not seen in brain or tumour, but
amounts < I of the liver level would not have been
detectable. Ro 07-0741 was readily detected in all 3 tissues.
Amounts at early times were similar and declined with a t2
of - 3 h. Interestingly, there was a clear trend towards
preferential retention in liver and tumour compared to brain,
possibly reflecting the degree of nitroreductive bioactivation.
Pharmacokinetics of melphalan in isolated limb perfusion
(ILP) for melanoma of the leg
R.N. Scott', R. Blackie2, D.J. Kerr2, J. Hughes',
R. Mackie3, S.B. Kaye2 & A.J. McKay'
Departments of 'Surgery and 2Medical Oncology, Gartnavel
General Hospital and 3Department ofDermatology, Western
Infirmary, Glasgow, UK.
The rationale for use of ILP in treatment of melanoma of
the leg depends on generation of high drug levels within the
lsolated limb and low systemic levels with enhancement of
the therapeutic ratio. The pharmacokinetics of melphalan
(dose= 1.5mgkg-1) have been studied in 10 patients with
lower limb melanoma who had external iliac ILP performed
for 1 h. The perfusate was sampled from arterial and venous
ports on the ILP pump and systemic blood specimens taken
from an indwelling radial catheter. Melphalan levels were
measured by a sensitive and specific HPLC assay. Peak drug
levels (44+ 12jgml -1) in the perfusate were considerably
higher than those achieved with maximal systemic therapy
(- 15-20pgml -'), and declined bi-exponentially. Partial
AUC analysis of patient and in vitro melphalan decay curves
indicated that there was no further drug uptake by the limb
after 30min of the 1 h perfusion and that -30% of the
administered melphalan dose distributed into the tissues of
the leg. Melphalan was virtually undectable in the systemic
circulation during the perfusion, but rose to a peak of
0.8 +0.6pgml- 30min after cessation of ILP. Systemic
clearance of melphalan was 0.18+0.04 1 min 2m-2, which is
lower than the expected value following systemic
administration. Our kinetic results show that high
concentrations of melphalan can be achieved within the
vascular compartment of the perfused limb and that drug
uptake by the limb seems to be saturated by mid perfusion.
Use of low dose methotrexate bolus to determine dosage in
high dose methotrexate therapy
M. Lough', G.J. Forrest2, N.L. Gilchrist2, I.D. Watson',
M. Soukop2 & M.J. Stewart'
Departments ofIPathological Biochemistry and 2Medical
Oncology, Royal Infirmary, Glasgow G4 OSF, UK.
The aim of this study was to individualise dosage on a
pharmacokinetic basis, utilising a low dose i.v. bolus of
methotrexate (MTX) (10mg) prior to high dose therapy
(1.5gm-2 over I h).
Six patients with high grade non-Hodgkin's lymphoma
were studied. Plasma MTX levels were followed for 24h
after low dose and high dose therapies. MTX levels were
measured by fluorescence polarisation immunoassay.
Comparison of high and low dose pharmacokinetics showed
that calculation of high dose MTX from low dose data was
no more effective than dosage based on body surface area
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Comparison of predicted plasma MTX concentrations (pmol1)
with the actual concentrations after high dose infusion
Patient EC SJ FW HH MB EF
Predicted
concentration 38.7 63.2 63.5 51.6 24.7 85.2
Measured
concentration 118 100 100 45 100 160
The disposition of vincristine, hepatic function and clinical
toxicity in children receiving infusion therapy
B.J. McDermott', C.R. Pinkerton2 & H.W. van den Berg'
'Department of Therapeutics and Pharmacology, The Queen 's
University of Belfaist, UK and 2Centre Leon Berard, Lyon,
France.
A Phase II study in children with resistant tumours showed
that the administration of a large dose of vincristine (VCR)
by long-term i.v. infusion had greater efficacy than a lesser
dose given as a bolus, but was associated with a larger
incidence of neurological toxicity. To assess the correlation
of these side-effects with pharmacokinetic parameters,
specimens of plasma were obtained from 9 patients who
received a loading of 0.5mgm-2 followed by a continuous
infusion of 0.5mgm 2 daily for 5 days. Concentrations of
VCR were determined using a radioimmunoassay of which
the lower limit of sensitivity was 0.25ngml-'. Biochemical
tests of liver function were performed before therapy, 1-4
times during treatment and up to 25 days after the end of
infusion.
The initial concentrations of VCR ranged from I-
II ngml- and of 5 cases with values >6ngml 1, 3 were
associated with abnormal neurological sensations during
treatment. The mean steady-state concentration was 1.68
(range, 1.29-2.15) ngml - I and delayed neuropathic
symptoms occurred in 1 of the 2 patients who had values
>2 ngml - 1. The total body clearance of VCR was not
related to levels of liver enzymes. The drug, however,
appeared to cause hepatocellular damage, indicated
particularly by the increase of y-glutamyltransferase to
abnormal levels in the majority of cases and usually after
completion of treatment.
Tyrosinase activity and the cytotoxic effects of 4-
hydroxyanisole in metastatic variants of the B16 melanoma
I. Oliver', A.J. Thodyl & and G.V. Sherbet2
'Department ofDermatology and 2Cancer Research Unit,
University ofNewcastle-upon-Tyne, Newcastle-upon-Tyne,
UK.
It has been suggested that the melanocytotoxic effects and
anti-tumour activity of 4-hydroxyanisole (4-OHA) are due to
its conversion by tyrosinase to toxic intermediates. In the
present study we have compared the cytotoxicity of 4-OHA
with levels of tyrosinase in 3 variants of the B16 melanoma.
B16FI, B16F1O and B16BL6 melanoma cells were cultured
in Eagles MEM with 10% fetal calf serum, antibiotics and
non-essential amino acids for up to 4 days. Under these
conditions, all cell lines expressed tyrosinase activity,
although the Fl cells displayed twice as much activity as the
other 2 lines. This difference was also seen in the amount of
tyrosinase in the bound form. Lower concentrations (10-6
and 10-5M) of 4-OHA had little cytotoxic activity in the 3
cell lines. Cytotoxicity was evident at 10- 4M 4-OHA and
most marked in the BL6. At 10-3M, cytotoxicity was similar
in all 3 cell lines. a-MSH (10 -' M) increased tyrosinase
activity in all 3 cell lines but had no effect upon the
cytotoxicity of 4-OHA.
These findings confirm that 4-OHA has cytotoxic
properties in melanoma cells. However, they do not support
the view that the cytotoxicity of 4-OHA is related to the
tyrosinase activity of the cell.
Phase I clinical pharmacokinetics of m-azidopyrimethamine
(MZP)
S.M. Crawford', R. Hoffman', J.A. Slack2,
G.R.P. Blackledge3, E.S. Newlands', N. Stuart3,
S.K. Wong2, S.K. Pashley2, C.J. Brindley' &
M.F.G. Stevens2
'Department ofMedical Oncology, Charing Cross Hospital
Medical School, London, 2CRC Experimental Chemotherapy
Group, Pharmaceutical Sciences Institute, Aston University,
Birmingham and 3CRC Clinical Trials Unit, Department of
Medicine, Birmingham University, Birmingham, UK.
Meta-Azidopyrimethamine ethanesulphonate (MZPES) is a
new lipophilic DHFR inhibitor designed to both overcome
transport-mediated resistance and possess a shorter
biological half than metoprin or etoprin. MZPES has been
shown to be active against P388(+), L1210(+ +),
B16(+ +), TLX5(+) and M5076(+ +) but inactive against
LL, CD8F, and Colon 38. MZPES has a Ki of 2.4nM
against L121ODHFR and 1.6nM against rat liver DHFR.
MZPES was formulated for clinical use as a 10% solution
in water and diluted into 500ml of 5% dextrose prior to i.v.
infusion over I h. The starting dose for Phase I evaluation
was 5.4mgm -2 and has been escalated through 11, 18, 27,
38, 50, 67, 83, 105, 125, 150, 180, 210, 250, 300, 360 and
400mgm 2 Pharmacokinetic studies have been performed
at all doses, except 5.4mgm-2 on a total of 34 patients with
the drug apparently obeying 2-compartment kinetics with no
evidence for dose dependency in the kinetics. The mean
distribution and elimination half lives were 0.26 and 33.52h
respectively with an apparent volume of distribution of 1191
and a central compartment volume of 261.
Disposition and anti-neoplastic efficacy of
niosome-encapsulated adriamycin in nude mice bearing lung
xenografts
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We have shown previously that the cellular uptake and
cytotoxicity of adriamycin in human lung tumour cells in
monolayer and spheroids is enhanced by concurrent
incubation with surfactant. Adriamycin has been
encapsulated in multilamellar, non-ionic, surfactant vesicles
(niosomes), - I pm in diameter. Free adriamycin solution
(10mgkg-1) or an equimolar amount of niosome entrapped
adriamycin was administered via a tail vein in nude mice
bearing a squamous lung tumour xenograft (WIL). At
intervals thereafter groups of 4 mice were sacrificed by
exsanguination and the tumour and organs removed for
subsequent drug analysis by HPLC. Tumour growth delay
was assessed by thrice weekly bidimensional measurement of
tumour size after intravenous treatment of 3 groups of 8
mice with free adriamycin (7.5mgkg-1), niosomal
adriamycin (7.5mgkg-1) and normal saline as control.
Respective mean peak adriamycin levels following
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administration of free or niosomal adriamycin were
statistically silila- in kidney (24.8 ig g ' v's. 11.3 jigg- 1),
liver (27.9 jig g -1 I's. 18.2 gg g1) and tumour (4.5 ugg 1 vs.
7.5pgg-), whereas peak plasma (0.12pgml-1 vs.
0.075pgml-1) and cardiac (1l.5ugg-1 vs. 5ugg-1)
concentrations were significantly lower in the niosome
treated group. Tumour volume doubling time was
significantly longer (P<0.05) for adriamycin (15 days) and
niosomal adriamycin (11 days) than for control (5.8 days),
although there was no difference between the treatment
groups. Since antitumour efficacy of adriamycin
encapsulated in adriamycin in niosomes is maintained, it is
conceivable that this mode of administration will lead to an
improved therapeutic index because of the potential
reduction in toxicity resulting from lower plasma and cardiac
drug levels.
Intravesical chemotherapy: Comparison of in vitro
cytotoxicities between monolayers and spheroids
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Drugs differ in their ability to penetrate tumours and this
factor will contribute to their relative value, for example, in
the treatment of superficial bladder cancer with intravesical
administrations. Three-dimensional multicellular tumour
spheroids provide an in vitro model for assessing drug
penetration. We compared the in vitro cytotoxicities
following a I h exposure to the 4 drugs most frequently used
for intravesical chemotherapy (adriamycin, epodyl,
mitomycin, thiotepa) and epirubicin using spheroids and 2-
dimensional monolayer cultures. We used the continuous cell
line MGH-U1, derived from a transitional cell carcinoma of
the human bladder, treating the monolayers and spheroids
(0.65-0.75 mm diam.) in an identical manner. The
concentrations of drugs which reduced clonogenic cell
survival by 50% are shown in the table.
IC50 monolayer IC50 spheroid
Drug (jPgml-') (,ugml-) Ratio
Adriamycin 0.20 2.90 14.50
Epirubicin 0.10 1.90 19.00
Epodyl 37.00 67.50 1.80
;Mitomycin-c 0.52 0.96 1.80
Thiotepa 29.00 13.00 0.45
Thiotepa was unique in being more cytotoxic in 3 than in
2-dimensional culture, and this finding is consistent with
clinical observations that this is the only drug penetrating
the bladder and consistently producing systemic toxicity.
Drug penetration is likely to have a major influence on
tumour cell kill, but other factors such as pH, oxygenation
and cell kinetics are important.
Interferon/drug combinations as anticancer therapy: What is
the optimum dosage schedule?
R.J. Ferguson, L.E. Anderson & J.F. Smyth
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Human alpha interferon (IFN) has been shown to potentiate
the activity of sub-optimal doses of certain cytotoxic agents
in human cancers grown in mice (Balkwill et al., Cancer
Res., 44, 904, 1984; Carmichael et al., Cancer Res., 46, 4916,
1986). Pilot clinical studies investigating the potential of
these combinations are currently being performed but little is
known about the optimum method of administering the
agents in combination. We studied the effect of different
dose schedules of cis-platinum (CDDP) and cIFN in
combination on a human squamous lung cancer xenograft in
immunodeprived mice. Groups of 8-10 tumours were
allocated to either treatment or control. IFN 2 x 104 Uday-l
was given s.c. for 35 days in combination with the MTD of
CDDP (7mgkg- I i.p.) given as (a) 1.4mgkg - I x 5 weekly,
(b) 3.5mgkg ' x2, 10 days apart, (c) a single 7mgkg
injection. The median doubling time for each group was
calculated and drug activity expressed in terms of the specific
growth delay (SGD). IFN alone had no effect but
potentiated both CDDP 1.4mgkg- 1 x 5 (SGD for CDDP
alone=0.88, for combination=2.00) and 7mgkg-1 x 1
(SGD=2.8, CDDP+IFN=3.1). The greatest effect was seen
with 3.5 mgkg- 1 x 2 where no tumours in the combination
group doubled (CDDP alone SGD =4.25). CDDP
(1.4mgkg 1 x 5) was then assessed with 3 doses of IFN
(5 x 104, 1 x 105, 2 x 105 Uday- 1). Maximum activity
(SGD=7.0) was seen with the middle dose (5 x 104,
SGD=4.3; 2 x 105, SGD=5.0; CDDP alone, SGD=0.75).
The optimum dosage schedule for IFN/CDDP combinations
in this model appears to involve chronic dosing at medium
levels rather than high or low doses of either agent.
Heat sensitivity of tumour tissue
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The effect of hyperthermia on MC7 sarcoma and D23
hepatoma, transplanted into rat foot, was studied in vivo and
in vitro. Heating in vivo delayed growth and in some cases
eliminated the tumour. Combined treatment of heat and
tetracine (a membrane fluidiser) caused a small potentiation
in survival of rats bearing MC7 and a large potentiation of
rats bearing the D23 tumour. Hyperthermia also affected a
number of membrane-associated functions: (a) Tumour and
liver slices were preincubated at a temperature between 37'
and 53"C for I h, then 02 uptake was monitored at 37"C.
Tumour respiration was inhibited after 44-46 C and so was
more thermosensitive than liver respiration. Inclusion of
tetracaine during the preincubation period sensitised tumour
respiration to heat. (b) Incubation of tumour tissue at 44'C
caused a marked rise in K+ leakage from cells compared
with incubation at 37 C. The inclusion of tetracaine
increased K+ loss by 3 to 4-fold in tumour and 1.3-fold in
liver. (c) Mg2+-ATPase (plasma membrane bound enzyme)
showed greater thermal sensitivity in tumour cells compared
with normal cells. Inactivation of the tumour enzyme
occurred in the range 42-50"C, whereas the liver enzyme was
inactivated only above 50"C. The 'fluidity' of plasma
membranes derived from the tumours and from normal liver
was measured by fluorescence polarisation using 1,6-diphenyl
1,3,5-hexatriene. Tumour plasma membranes were more
'fluid' (decreased order) than liver membranes at all
temperatures tested. Tetracaine decreased membrane order in
both tumours and in liver. Collectively these data support
the hypothesis that the plasma membrane is a primary target
in heat injury and that the tumour cell membrane may be
particularly susceptible to hyperthermia as a result of the
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